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Zusammenfassung 
 
Neue Generationen von bindenden Molekülen, die nicht auf dem 
Immunglobulin-Gerüst basieren, sind zu einer attraktiven Alternative zu 
Antikörpern geworden. Während die Spezifität von Antikörpern erhalten bleibt, 
bieten diese neuen Generationen von Bindungsproteinen mehrere Vorteile 
gegenüber Antikörper in Bezug auf molekulare Robustheit als Voraussetzung für 
z.B. Affinitätsmaturierung, sowie Stabilität und Wirtschaftlichkeit der Produktion. 
Ein Beispiel für eine solche Alternative sind Designed Ankyrin Repeat Proteine 
(DARPin). Der Schwerpunkt dieser Arbeit war die Generierung von spezifischen 
DARPins, die das tumorassoziierte Antigen EpCAM (epithelial cell adhesion 
molecule) erkennen, und deren Verwendung als Trägersubstanz für ein Biotoxin 
zur tumorgerichteten Therapie. Die Wahl von EpCAM als Zielstruktur beruht auf 
dessen vorteilhaften Eigenschaften als Bindungsstellen auf Tumorzellen wie zum 
Beispiel die Überexpression in zahlreichen soliden Tumoren, der geringen 
Expression und anatomisch bedingten schlechteren Zugänglichkeit in normalen 
epithelialen Geweben, der stabilen Expression ohne "shedding" und der 
Fähigkeit, nach Ligandenbindung in die Zelle zu internalisieren. All diese 
Eigenschaften machen EpCAM zu einer idealen Zielstruktur für die 
tumorgerichtete Behandlung mit hochzytotoxischen Krebsmedikamenten 
einschliesslich Biotoxine, die ohne diese Tumorselektivität nicht anwendbar sind. 
Das günstige therapeutische Fenster EpCAM-spezifischer Krebstherapien wurde 
bereits in früheren Studien bestätigt. 
Der erste Schritt zum spezifischen EpCAM Targeting war die Selektion und 
Charakterisierung von DARPins, die gegen die extrazelluläre Domäne von EpCAM 
gerichtet sind. Phage-Display- und Ribosome-Display Methoden wurden 
angewandt, um eine erste Generation von Bindern gegen EpCAM zu erhalten, die 
anschliessend durch Affinitätsreifung noch weiter verbessert wurden. Die zweite 
Generation von Bindern wurde charakterisiert, und die sechs besten EpCAM-
spezifischen DARPins wurden ausgewählt. Sie waren sehr gut exprimierbar, 
monomerisch und erkannten nicht nur das lösliche EpCAM, sondern konnten 
auch im zellulären Kontext an EpCAM binden. Basierend auf der Affinität, 
wählten wir einen dieser Binder, EC4, zur weiteren Analyse als Targeting-Einheit 
für die EpCAM-gerichtete Krebsbehandlung mit einem hochgiftigen Biotoxin. 
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Hierfür wurde Ec4 C-terminal mit einer verkürzten Form des Pseudomonas 
Exotoxin A (ETA) ohne dessen bindende Domäne fusioniert. Ec4-ETA" war löslich 
und in grossen Mengen im Zytoplasma von E. coli exprimierbar. Der Vorteil der 
Verwendung eines DARPins für die Generierung des Fusionsproteins wird 
dadurch verdeutlicht, dass dieses Fusionstoxin zu einer 50 mal höheren 
Ausbeute und wesentlich vereinfachter Aufreinigung führte, verglichen mit 
einem EpCAM-spezifischen scFv, der mit ETA" fusioniert ist und im Periplasma 
exprimiert wurde. Nach biochemischer Charakterisierung des DARPin-ETA'' 
Fusionsproteins wurde die Zytotoxizität gegen Tumorzellen in vitro und in vivo 
analysiert. EC4-ETA" erwies sich als hochzytotoxisch gegen verschiedenen 
humane Krebszellen, dabei war dieser Effekt abhängig von der Expression von 
EpCAM. So wurde nur eine sehr geringe Hintergrundaktivität gegen EpCAM-
negative Zellen gemessen und die Zytotoxizität von Ec4ETA" wurde auch durch 
Zugabe von löslichem EC4 DARPin als Kompetitor gehemmt, nicht aber durch 
Zugabe eines unspezifischen DARPins. In vivo Fluoreszenz-Bildgebung in 
Nacktmäusen mit subkutan wachsenden HT29 Kolonkarzinomen zeigte, dass sich 
EC4-ETA" in Tumoren ansammelt mit Maximalwerten 48 bis 72 Std. nach 
intravenöser Injektion, während eine unspezifische DARPin ETA"-Fusion keine 
Tumorlokalisation zeigte. Dieses günstige Tumorlokalisierungsprofil korrelierte 
direkt mit der Antitumoraktivität des Fusionstoxins, so kam es nach Injektion von 
Ec4-ETA" in gut verträglicher Dosierung zu einer deutlichen Hemmung des 
Wachstums der Kolonkarzinome mit vereinzelt sogar kompletten Regressionen.  
Zusammenfassend haben wir erstmals hochaffine und stabile EpCAM-
spezifische DARPins hergestellt und charakterisiert. Am Beispiel einer 
hochzytotoxischen DARPin-Biotoxin Fusion konnten wir zudem deren Eignung für 
die tumorgerichtete Krebstherapie in vitro und in vivo demonstrieren. 
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Summary 
 
New generations of binding molecules not based on the immunoglobulin 
scaffold have become an attractive alternative to antibodies. While keeping the 
same affinity and specificity of antibodies, they can provide several advantages 
over them concerning robustness, stability and economy of production. An 
example of such an alternative scaffold is the Designed Ankyrin Repeat Protein 
(DARPin). The focus of this thesis was on the generation of specific DARPins 
recognizing the clinically validated tumor associated antigen epithelial cell 
adhesion molecule (EpCAM) and their use as a vehicle for the delivery of a highly 
potent biotoxin. The choice of EpCAM as a target was based on its favorable 
characteristics as a tumor associated antigen such as overexpression in 
numerous tumor types, low expression and poor accessibility on normal tissues, 
no considerable shedding or downregulation and its ability to internalize upon 
ligand binding. All these characteristics make EpCAM an ideal target for the 
tumor-targeted delivery of cytotoxic payloads. Moreover, the reasonable 
therapeutic window offered by EpCAM targeting has been demonstrated by 
several approaches. 
The first step to achieve highly specific targeting of tumor cells was the 
selection and characterization of DARPins against the extracellular domain of 
EpCAM. Phage display and ribosome display were applied to obtain a first 
generation of EpCAM binders which were then further improved by affinity 
maturation. The second generation of improved binders was characterized and 
the six best EpCAM-specific DARPins were chosen. They could prove to be well 
expressing monomers and recognized EpCAM not only in soluble form, but also 
bound to epitopes accessible in the cellular context. 
Based on the affinity, we chose one of these binders, Ec4, for further 
analysis as a vehicle for targeted delivery of a highly potent biotoxin to human 
tumor cells. To this end, Ec4 was C-terminally fused to a truncated form of 
Pseudomonas exotoxin A (ETA") lacking the cell binding domain. Ec4-ETA" was 
expressed in soluble form and at high yields in the cytoplasm of E. coli. The 
advantage of using a DARPin for the generation of the fusion protein was thus 
convincingly demonstrated by a 50-fold higher production yield, and more 
simplified purification steps compared to its counterpart, an EpCAM-specific 
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scFv-ETA" immunotoxin, which in soluble form only expressed in the periplasm. 
Upon biochemical characterization, the DARPin-ETA’’ fusion protein was 
analyzed for cytotoxicity and antitumor activity in vitro and in vivo. Ec4-ETA" was 
highly cytotoxic to a EpCAM-positive tumor cell lines of various histotypes. This 
effect was EpCAM-dependent, as cytotoxicity was reduced to background levels 
on EpCAM-negative cells and further analysis revealed that it was also abolished 
upon addition of soluble Ec4 as competitor, but not an irrelevant unspecific 
DARPin. In vivo fluorescence imaging in nude mice bearing human HT29 colon 
carcinoma xenografts demonstrated that Ec4-ETA" accumulated in tumors with 
peak levels achieved 48 h to 72 h after injection, whereas an irrelevant unspecific 
DARPin-ETA fusion did not show tumor localization. The favorable tumor 
targeting of properties of Ec4-ETA" also translated into potent antitumor activity 
resulting in a strong inhibition of tumor growth at well-tolerated doses with 
some mice showing even complete regressions. 
In conclusion, we generated and characterized for the first time EpCAM-
specific DARPins of high affinity and stability, and in the form of a second 
generation fusion toxin as example demonstrated their potential for use in 
tumor targeting and therapy. 
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Cancer 
 
Cancer remains the second most common cause of death in our society. 
Approximately 10 million people worldwide are diagnosed with cancer each 
year. There are more than 100 distinct types of cancer and within them, 
subtypes of tumors can be found. Lung and colorectal cancers are the most 
common cancers in both men and women, followed by breast cancer in women, 
and prostate cancer in men (Figure 1). In addition, metastatic cancers constitute 
the main threat of cancer to life and its management remains one of the most 
challenging aspects for oncologists. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Ten Leading Cancer Types, 2009 (1) . Lung cancer is the most common fatal 
cancer in men followed by prostate, and colon & rectum. In women, lung, breast, and 
colon & rectum are the leading sites of cancer death. ONS: other nervous system.  
 
 
Lung & bronchus  30% 
Prostate   9% 
Colon & rectum   9% 
Pancreas  6% 
Leukemia  4% 
Liver & intrahepatic 4% 
bile duct 
Esophagus  4% 
Urinary bladder  3% 
Non-Hodgkin 
Lymphoma  3% 
Kidney & renal pelvis 3% 
All other sites  25% 
 26% Lung & bronchus 
 15% Breast 
 9% Colon & rectum 
 6% Pancreas 
 5% Ovary 
 4% Non-Hodgkin 
  lymphoma 
 3% Leukemia 
 3% Uterine corpus 
 2%  Liver & intrahepatic 
  bile duct 
 2% Brain/ONS 
25%    All other sites 
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Cancer is a genetic disease arising from mutations in regulatory genes 
which result in a loss of growth control and consequently confers a survival 
advantage to the tumor cells. Cancer develops as a multistep process in which a 
succession of genetic changes leads to progressive conversion of a normal 
human cell into a cancer cell (2). As described by Hanahan and Weinberg (3), 
there are six essential alterations in cell physiology acquired during tumor 
development. These hallmarks are: the ability to proliferate independently of 
growth signals, the avoidance of programmed cell death (apoptosis), the 
insensitivity to growth suppressive factors, the ability to stimulate and sustain 
angiogenesis, the ability to invade tissue and to metastasize, and their limitless 
replicative potential. Recently, the inflammatory microenviroment around the 
cancer cell has been included as the seventh hallmark of cancer (4). 
 
 
Cancer treatments 
 
 
Conventional therapies  
 
Conventional therapies to treat cancer such as surgery, radiation and 
chemotherapy have served well during many years in the battle against cancer. 
Chemotherapeutic drugs either alone or in combination with radiotherapy have 
improved the outcome of several solid or hematologic tumors. However, in spite 
of continuous advances, these therapies are limited and not without significant 
side effects. 
Surgery is only suitable when treating cancer in localized areas or when 
tumors are accessible, but not when tumors have already spread through the 
body. Radiation does not discriminate between tumor cells and healthy tissues. It 
destroys all cells in the area being treated and relies on externals methods to 
find the desired location and to minimize harm to nearby healthy tissues. 
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Chemotherapy interferes with the ability of rapidly dividing cells to grow, a 
characteristic of cancer cells. However, healthy cells are also affected, especially 
those rapidly dividing cells like the skin, the lining of the stomach, the intestines 
and bone marrow. Therefore, the major limitation of these therapies is the lack 
of tumor specificity and toxicity to normal tissues. Suboptimal doses have to be 
given, leading to failure of the therapy or to drug resistance. To overcome the 
limitations of conventional therapies there is a need to develop new cancer 
treatments.  
 
 
Targeted therapies 
 
The greater understanding of mechanisms of how cancer cells operate, 
how they become malignant and of their antigenic profile contributes greatly to 
the design of therapies that target tumors more specifically. The identification of 
factors that influence the carcinogenic process led to the discovery of a number 
of critical steps that can be targeted for therapeutic intervention. As a result, 
normal cells are spared and thus very little associated toxicity is expected. 
Several types of targeted therapies are under development and some of them 
haven been approved for cancer treatments (5). Some of these approaches 
include: small molecule drugs with greater specificity (6), cancer vaccines (7), 
gene therapy (8), drug carriers such us liposomes or nanoparticles (9), and ligand 
or antibody-based therapies (10) (Figure 2).  
Among the targeted therapies, antibody-based therapies have become a 
major strategy in clinical oncology. In general, this targeting system consists of 
two parts: 
• The tumor antigen which is the targeted molecule. 
• The targeting moiety: mostly an antibody or antibody fragment, 
but growth factors, cytokines and ligands are also used. This 
moiety may act by itself or may serve as a vehicle for the deliver 
of a cytotoxic agent.  
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Figure 2. Different types of targeted cancer therapies. Antibody based 
therapies: unconjugated antibodies can produce their effect either by blocking 
receptors or marking the cells to be recognized by the immune system. 
Antibodies can also serve as vehicles to deliver antitumor agents, such as 
radioisotopes, toxins or cytotoxic compounds. Another approach is to inhibit 
signaling pathways important for tumor growth by small-molecules drugs. Gene 
therapy holds promise for blocking expression of oncogen or repairing of tumor 
repressor genes. Antisense oligonucleotides can block protein synthesis by 
binding to specific mRNA sequences. Selective targeting of ligand-targeted 
liposomes and nanoparticles containing anticancer drugs is another strategy to 
improve the therapeutic effectiveness of these drugs. Figure adapted from 
Segota et al. (5). 
 
 
 
The importance of the targeted antigens  
 
The therapeutic efficacy of the drug used in a targeted therapy depends 
in great part on the properties of the targeted antigen. Due to tumor 
heterogeneity and similarity to normal tissues, identification of truly specific 
tumor antigens is a very difficult challenge. Most of the characterized antigens 
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are considered to be associated to tumors but to some extent are also present 
on normal cells. Tumor-associated antigens (TAAs) are mostly derived from 
mutated or differentially expressed proteins between tumor and normal cells. 
Characteristics that make a TAA an ideal candidate for targeted therapy include: 
 
• High level and frequency of expression on tumor cells and low 
expression or inaccessibility on normal cells.  
• No loss or reduction of antigen expression during tumor 
development and progression or by chemotherapeutic treatments 
• Absence of substantial antigen shedding 
• Accessibility to the targeted drug 
 
Many TAAs have been identified and characterized (11). They are used in 
the detection, diagnosis and treatment of a variety of cancers. Some examples 
are summarized in Table 1. Among them, one promising TAAs which fulfills the 
criteria to be used for targeted therapies is the epithelial cell adhesion molecule 
(EpCAM) and will be described more in detail.  
 
 
EpCAM 
 
EpCAM is a 40 kDa transmembrane glycoprotein consisting of an 
extracellular domain of 246 amino acids, a 23 amino acid transmembrane 
domain and a short intracellular domain of only 26 amino acids. The extracellular 
part of EpCAM comprises an epidermal growth factor (EGF)-like domain and a 
human thyroglobulin (TY)-like domain followed by a cysteine-poor region (23-
25).  
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Table 1. Some examples of TAAs used for the detection, diagnosis and treatment of 
different cancers 
TAAs Overexpression in 
CEA Several solid tumors: 
colorectal, gastric, pancreatic, NSCLC, esophageal and 
breast cancer (12) 
CA125 ovarian cancer (13) 
PSCA prostate cancer (14) 
HER2/neu Several solid tumors: 
breast, ovarian, gastric and colorectal carcinomas (15) 
MUC-1 colon and breast cancer (16) 
EGFR Several solid tumors: 
non-small-cell-lung cancer (NSCLC), prostate, breast, 
stomach, colon, ovary and head and neck (17-18) 
EpCAM Several solid tumors: 
colon, breast, NSCLC, head and neck, bladder, and 
prostate cancer (19-21) 
CD25 (IL2-receptor), CD22 Hematological malignancies (22) 
Abbreviations used: CEA: carcinoembryonic antigen, CA-125: cancer antigen 
125, PSCA: prostate stem cell antigen, HER2/neu: human epidermal growth factor 
receptor 2, MUC-1: mucin 1, EGFR: epidermal growth factor receptor, EpCAM: epithelial 
cell adhesion molecule, CD: cluster of differentiation, IL: interleukin  
 
 
EpCAM was discovered more than 30 years ago (26); its function was 
proposed as a calcium-independent cell adhesion molecule (27). It was shown 
that it can interfere with the function of other cell adhesion molecules. 
Regulation of E-cadherin junctions may be one of the pathways by which EpCAM 
affect cell differentiation and promote cell invasion (28). A hypothetical model 
proposed for the structure of EpCAM mediated adhesions in the cell membrane 
is the formation of tetramers with lateral and reciprocal interactions (29) (Figure 
3). But restricting EpCAM function to be only a cell adhesion molecule could not 
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explain its increased expression in several tumors and its negative correlation 
with survival prognosis (30-31). Recently, EpCAM was described as a "surface-to-
nucleus missile" (32) to explain its involvement in nuclear signaling. EpCAM is 
cleaved via regulated intramembrane proteolysis (RIP) by two enzymes, the 
tumor necrosis factor-alpha-converting enzyme and a gamma-secretase 
complex. The released cytoplasmatic domain induces the transcription of c-myc, 
cyclins and genes related to proliferation. Activation of EpCAM was found by 
soluble EpCAM or in zones of cell-cell contact, indicating that its oligomerization 
might trigger activation (33-35). Thus, it seems clear now that EpCAM has a dual 
role, both as an adhesion molecule as well as an oncogenic signal transducer. In 
addition, recent studies have identified a number of proteins that directly or 
indirectly interact with EpCAM, such as CD44v4-v7, and claudin 7 (36-39). Some 
of these interactions appear also to be involved in processes that promote 
carcinogenesis. 
The presence of high levels of EpCAM has been well defined in a variety 
of solid tumors such as colon, breast, prostate, head-and-neck, lung and others 
(19-21, 40-42) and for this reason is considered one of the most frequently 
expressed TAA. Although it is expressed in some normal epithelial tissues, it is 
mostly located on the basolateral cell surface (23, 43). This location makes 
EpCAM in normal tissues less accessible than in tumor tissues where it is 
homogenously distributed (44). Moreover, EpCAM overexpression usually 
correlates with a decreased survival representing a negative prognostic marker 
for patients with breast, ovarian, gall bladder and head and neck tumors (30, 42, 
45-46) 
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Figure 3. Revised model of EpCAM on the cell membrane (47). EpCAM is shown 
as a tetramer and each polypeptide chain is depicted with a bend within the TY 
domain and  the EGF-like domain is oriented to the membrane. The cleavage site 
of EpCAM proteases are shown with arrows in red.  
 
New data reveal that in several types of cancer, only a subset of cancer 
cells is capable of initiating tumor growth. This subpopulation of cells is defined 
as cancer stem cells (CSCs). They have the ability to self-renew and to 
differentiate, thereby generating the primary tumor and to disseminate to 
produce metastatic disease (48). Recently, EpCAM has been also identified on 
CSCs from a variety of cancer types such as breast, colon and pancreas (49-52). 
The concept of CSCs has a profound implication for cancer therapies (53): if the 
tumor growth is driven and maintained by CSCs, a major goal of cancer therapy 
will be to identify and kill these cells. Consequently, markers allowing the 
identification and of CSCs will become of great importance as CSCs usually 
respond poorly to standard chemotherapy. 
Currently, at least seven candidate therapeutics focus on EpCAM as a 
target and are under clinical development (47). Many other approaches are 
under pre-clinical evaluation. Some of these approaches involve monoclonal and 
bi/tri specific antibodies (54-55), vaccination approaches (56), toxin fusion 
proteins (57-58), and drug-filled targeted liposomes (59). 
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In summary, the favorable properties of EpCAM as a tumor-associated 
antigen, its role in promoting cell proliferation, its presence on CSCs, and the 
increasing numbers of EpCAM-directed therapies which are under development, 
strongly support its use as a therapeutic target antigen for the eradication of 
both differentiated and pluripotent cancer cells. 
 
 
Antibodies as the tumor recognition moiety 
 
For tumor targeted therapies monoclonal antibodies (MAbs) can be used 
in two different ways: as unconjugated molecules (naked antibodies), or coupled 
to effector molecules such as radionuclides, enzymes, drugs, cytokines, toxins 
and drug-filled liposomes or nanoparticles (60-61). Consequently, their 
mechanisms of action depend on how the antibody is used, the antibody itself 
and the targeted antigens. 
 
 
Unconjugated or naked monoclonal antibodies  
 
Antibodies alone are usually not responsible for killing tumor cells. They 
bind to TAAs thereby either initiating signaling mechanisms that induce 
apoptosis in tumor cells, or marking tumor cells. Subsequently, the immune 
system recognizes tumors cells to which antibodies are bound and Fc domain-
based functions are activated such as antibody-dependent cellular cytotoxicity 
(ADCC) or antibody-dependent complement mediated cytotoxicity (CDC). 
Antibodies can also bind to a specific epitope, thereby blocking the binding of the 
natural ligand preventing growth-promoting signals. Another example of how 
antibodies can be used therapeutically is the binding to a soluble growth 
promoting factor such as the vascular endothelial growth factor preventing the 
formation of new vessels in the tumors (62). Unconjugated antibodies approved 
18 
 
by the U.S. Food and Drug Administration (FDA), their targets, indication and 
their probable mechanisms of action are summarized in Table 2. 
Although unconjugated MAbs show some therapeutic potency, they are 
seldom curative by themselves. Mostly they are used in combination with 
chemotherapeutic agents to increase the response rate and the efficacy of the 
therapy (63). One strategy to increase the therapeutic potency of antibodies is to 
use them as a transport vehicle for more potent anticancer drugs (10, 64). 
 
Table 2. Unconjugated monoclonal antibodies used for cancer treatment (FDA 
approved) 
Abbreviations used: EGRF: epidermal growth factor receptor, HER2: human 
epidermal growth factor receptor 2, VEGF: vascular endothelial growth factor. 
 
Antibody 
Brand 
name 
Target 
Probable 
mechanisms of action 
Indicated for 
Rituximab Rituxan® CD20 
Triggers immune response 
and induction of apoptosis 
by crosslinking 
B-cell non-Hodgkin's 
lymphoma 
Trastuzumab Herceptin® HER2 
Induction of the immune 
system and prevention of 
growth-promoting signaling 
Breast cancer 
Cetuximab Erbitux® EGFR 
Inhibition of signal 
transduction 
Squamous cell 
carcinomas of the 
head and neck and 
colorectal cancer 
Panitumumab Vectibix® EGFR 
Inhibition of signal 
transduction 
Metastatic colon 
cancer 
Alemtuzumab Campath® CD52 Triggers immune response 
B-cell chronic 
lymphocytic 
leukemia 
Bevacizumab Avastin® VEGF Block angiogenesis Colorectal cancer 
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Monoclonal antibodies as delivery vehicles for cytotoxic drugs 
 
The rationale for using antibodies as delivery vehicles for toxic payloads is 
to combine the power of potent cytotoxic agents with the specificity of 
antibodies. These cytotoxic drugs, which are too potent to be used alone, can be 
selectively delivered to tumors using antibodies as targeting moieties. The main 
goal is to increase the amount of drug at the tumor site and decrease them at 
the healthy tissue. In addition, antibodies which are tumor specific but too little 
toxic to tumors, can acquire a higher toxic potential when fused to cytotoxic 
compounds. Accordingly, cytotoxic drugs, cytokines, radionuclides, enzymes and 
toxins have been conjugated to antibodies and evaluated in preclinical and 
clinical settings. At present there is one FDA-approved immunoconjugate 
containing a cytotoxic drug: gemtuzumab (Mylotarg®), consisting of a humanized 
anti CD33 mAb conjugated to the potent antibiotic calicheamicin (65). Two 
radiolabeled mAbs have been approved for the treatment of B-cell lymphomas: a 
CD20-specific antibody radiolabeled with 90Y (ibritumomab tiuxetan, Zevalin®) 
(66) and a CD20-specific antibody radiolabeled with 131I (tositumomab, 
Bexxar®)(67-68). Additionally, in 1999 the FDA approved the used of the first 
toxin conjugate: denileukin difitox, Ontak® for the treatment of patients with 
persistent or relapsed CD25-positive cutaneous T-cell lymphoma (69). Ontak is 
composed of the full length IL-2 ligand fused to a truncated form of Diphteria 
toxin. Targeting tumors using toxins fused to antibodies is a promising strategy to 
enhance antitumor activity of antibodies. 
 
 
Antibodies conjugated to toxins: immunotoxins 
 
Toxins are really potent cytotoxic agents requiring only few molecules to 
kill a cell. Their potency is based on their catalytic activity with a high turnover 
rate, robustness to survive proteolytic degradation and an ability to interact with 
essential components of most cell types (70). Due to these properties, toxins 
produced by bacteria (e.g., Diphtheria toxin, Pseudomonas exotoxin A), or by 
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plants (e.g., gelonin, ricin, abrin) are used as anticancer agents (71). However, 
used alone they are toxic to many cells in the body. To widen their therapeutic 
window, they need to be targeted to cancer cells. To this purpose, TAA-specific 
antibodies can be conjugated to a toxins and redirect the cell-killing activity 
specifically to cancer cells only. These chimeric proteins, consisting of a targeting 
moiety, most frequently antibodies but also growth factors or interleukins, and a 
toxin moiety, are termed immunotoxins (ITs). 
The first generation of ITs was developed by chemically conjugating 
whole toxins to antibodies (72) . Although they demonstrated the feasibility of 
the concept, they were ineffective due to a lack of specificity: toxins could still 
bind to healthy cells and thus kill them. Moreover, they showed poor stability 
and heterogeneous composition. In the second generation of ITs, by applying 
knowledge of toxin structures the cell-binding domain of the toxin was removed 
before conjugation with antibodies. This reduced the unspecific toxicity to 
normal cells but as they were still made by chemical coupling, heterogeneity 
remained a problem. The third generation has overcome this problem by making 
use of the advances in recombinant DNA techniques. Mostly antibody fragments, 
scFv or dsFv, are genetically fused to truncated form of the toxins. Thus, it is 
possible to generate homogenous products and also decrease the size of the ITs 
by using small antibody fragments, thereby improving tumor penetration. 
A large number of clinical trials have been conducted with ITs over the 
last years. These ITs recognize a wide variety of TAAs present on hematological 
malignancies and solid tumors (71). However, immunogenicity and unspecific 
toxicity represent the two principal challenges that limit the effectiveness of ITs. 
Antibodies or antibody fragments are usually humanized; therefore, the 
immunogenicity is in most cases related to the toxin part of the IT. As toxins are 
foreign proteins, the human immune system may develop neutralizing antibodies 
against them. The binding of antibodies to ITs results in loss of efficacy and 
precludes repeated treatment, limiting ITs therapeutic application. IT-based 
therapies have been more effective in hematological malignancies like 
lymphomas and leukemias. These diseases are normally immunosuppressive 
and, as a consequence, the generation of neutralizing antibodies is less frequent 
(73). However, in the treatment of solid tumors neutralizing antibodies are more 
frequently present. Several approaches are being investigated to reduce 
immunogenicity, e.g. the use of immunosuppressive agents or monoclonal 
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antibodies such as rituximab, which depletes normal peripheral B cells (74). 
Another approach is to attempt to identify the immunogenic sequences of the 
toxin and generate less immunogenic variants which still retain their full 
cytotoxic activity (75-76). The generation of toxins chemically conjugated with 
polyethylene glycol (PEG) (77) to shield the protein's immunoreactive sites is as 
well a possible alternative to overcome this problem. Probably, the combination 
of these approaches and others will allow repeated treatment schedules 
increasing the amount of the ITs at the tumor site.  
Unspecific toxicity can be related to the targeting moiety when it is not 
specific enough for its target but cross-react with other antigens, or when the 
same target cancer antigen is present in high amounts on normal tissues. This 
can become a serious problem if these antigens are present in vital organs. 
Normally, this is ruled out in the extensive preclinical testing of ITs. However, it is 
noteworthy to mention how crucial the choice of the right TAA to be targeted 
and the specificity of the targeting moiety in the development of ITs are. 
Nevertheless, most of the unspecific effects related to ITs are associated with the 
toxin moiety itself. Vascular leak syndrome (VLS) and/or hepatotoxicity are 
frequently the dose-limiting toxicities (78). VLS is the result of endothelial cell 
damage increasing vascular permeability and producing a fluid leakage from 
capillaries. Edema, hypotension and hypoalbuminemia are signs of VLS, 
pulmonary edema and cardiovascular failure being the most severe 
consequences. Amino acid sequences that are thought to be responsible for VLS 
have been proposed (79) and several approaches are currently being 
investigated to test whether VLS can be diminished during IT treatment. Liver 
injury might be the result of the sensitization of hepatocytes toward TNF 
production by Kupffer cells after toxin activation (80), although liver toxicity has 
been shown in other cases to be related to the presence of the target antigen in 
the liver (81).  
Probably new generations of ITs, targeting more specific TAAs, in 
combination with toxins which are modified to be less immunogenic and to 
produce less unspecific toxicity will further improved the application of ITs and 
yield new treatment options. 
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Pseudomonas exotoxin A 
 
Pseudomonas exotoxin A (ETA, PE), is one of the most frequently used 
toxins for the generation of ITs (82). ETA is a 66 kDa protein produced by 
Pseudomonas aeruginosa as a single polypeptide chain. It is organized in three 
structural and functional domains (Figure 4). The N terminal domain (domain Ia) 
is responsible for binding to the alpha 2-macroglobulin receptor/low density 
lipoprotein receptor-related protein (α2MR/LRP), a receptor present in the 
majority of the cells. Domain II mediates the translocation of domain III, the 
enzymatic domain, into the cytosol of the cells. Domain Ib is located between 
domain II and III and has at present no known function (83). 
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Figure 4. Pseudomonas exotoxin A (ETA) A) Schematic representation of ETA 
domains: the receptor binding domain (green), the translocation domain (blue) 
and the catalytic domain (red). The furin cleavage site (aa 274-280), disulfide 
bonds and  ER retention sequence at the C-terminus are depicted. B) Three 
dimensional structure of ETA. domain Ia (1-252), purple b-sheet, yellow a-helices 
and coils; domain Ib (365-404), green b-sheet and coil; domain II (253-364), light 
blue b-sheet and coil; and domain III (405-613), red a-helix and coil, blue b-sheet. 
Cyan spheres represent Na ions; yellow spheres represent Cl ions; disulfide 
positions are indicated as green spheres. C) Stereographic Cα representation. 
Spherical main-chain atom positions are numbered every 20 amino acid residues. 
Color scheme and orientation based on (a). Disulfide positions are indicated as 
ball-and-stick side-chains. An arrow indicates the site of furin cleavage. Figure 
adapted from Wedeking et al.(83) 
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The first step of cell intoxication by ETA is its internalization by receptor-
mediated endocytosis (Figure 5). Once in the endocytic compartment, it 
undergoes a conformational change and it is cleaved by furin, an endosomal 
protease (84-85). This generates two fragments which are still bound by a 
disulfide bridge (cys265-cys287). After reduction of this disulfide bond, a 37 kDa 
fragment containing the catalytic domain and an ER retrival sequence at (REDL) 
at its C-terminus, is transported from the early endocytic compartment to the 
late endosomes and to trans-Golgi network (TGN) in a Rab9 dependent manner. 
There, it binds to the KDEL receptor using its KDEL-like sequence, and is 
transported to the ER. Via this 'reverse secretory' intracellular pathway mediated 
by the retention sequence, ETA probably can access to the ER and translocate to 
the cytosol. Accordingly, analysis of several mutants demonstrated that variants 
with the highest affinity to the KDEL receptor showed the highest cytotoxicity 
(86). Alternatively, ETA bound to the α2MR/LRP receptor has been found in 
detergent resistant microdomains and it is likely that this fraction of the toxin 
can follow the direct EE to TGN pathway exploit by other lipid-binding proteins. 
This alternative pathway avoiding late endosomes (LE) might be cell specific 
depending on the amount of receptors that are recruited to DRM (87). Once the 
37 kDa fragment translocates to the cytosol, it catalyzes the ADP ribosylation of 
the eukaryotic elongation factor -2 (eEF-2) (88). This ADP ribosylation inactivates 
the eEF-2 resulting in irreversible protein synthesis inhibition and cell death 
(Figure 5). 
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Figure 5. Mechanism of intoxication of Pseudomonas exotoxin A (ETA). After 
ETA binding to its receptor (α2MR/LRP), internalization occurs by clathrin coated 
pits (CCP) or via caveosomes (CS), in a Rab5-dependent manner, when ETA 
bound to the receptor is localized in detergent resistant microdomains (DRM). 
After processing inside of the endosomes (EE), the 37 kDa catalytic domain 
travels to the endoplasmatic reticulum (ER) via the trans-Golgi network (TGN) ), 
in a Rab9 or Rab6 dependent manner. This domain is now secreted to the 
cytoplasm via the translocon Sec61p, where ADP-ribosylates the elongation 
factor 2 (eEF-2) leading to cell death. CM: cell membrane, PDI: disuldide 
isomerase, Chap: chaperones, LE: late endosome. (Figure adapted from Wolf et 
al., (78)) 
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Pseudomonas exotoxin A-based immunotoxins 
 
The elucidation of ETA’s toxicity mechanism and of its molecular structure 
has allowed the generation of several immunotoxins. When domain Ia is 
removed from ETA to generate a 40 kDa protein, the cytotoxicity is abrogated 
(89) because ETA has lost its ability to bind to its cellular receptor. Taking 
advantage of this fact, the 40 kDa fragment can be genetically fused to specific 
targeting moities to redirect the toxic activity of ETA to desired target cells. 
Moreover, it has been demonstrated by mutants generated of a chimeric protein 
composed of TGFα fused to the different fragments of ETA that a portion of 
domain Ib can be additionally removed (aa 360 to 380) without lost in 
cytotoxicity (90). This generates a 38 kDa fragment which can also be used in the 
preparation of ITs. Although the function of domain Ib is still not clear, this is an 
indication that this domain is not essential for cell toxicity. It may be probably 
that domain Ib is required for intoxication when domain Ia is present (as they are 
close in the three dimensional structure of ETA). It might also be possible that 
domain Ib is necessary for secretion of ETA from Pseudomonas aeruginosa. The 
replacement of ETA carboxy-terminal sequence, REDLK, by the ER retrieval 
sequence KDEL, enhances ETA toxicity (86, 91). 
Several ETA-based ITs are being evaluated in preclinical trials and some 
have entered into clinical trials for the treatment of various cancers (78). Some 
examples are briefly described.  
Promising IT clinical data have been obtained using BL-22 for the 
treatment of hairy cell leukemia (92). BL-22 (RFB4 dsFv-PE38) consists of a dsFv 
directed to the CD22 antigen fused to the truncated form of ETA, PE38. BL-22 has 
been investigated in phase I with complete remission in the majority of the 
patients. A phase II trial has been completed which has confirmed the phase I 
results. In addition, a high-affinity mutant of BL22 (HA22) is in phase I testing 
(93). 
LMB2 (Anti-Tac (Fv)-PE38KDEL) targets the alpha subunit of IL-2R and 
contains PE38 as the toxin moiety. LMB-2 was given to patient with 
chemotherapy-resistant leukaemia, lymphoma and Hodgkin disease in a phase I 
trial. It was the first IT that showed benefit for patients with hairy-cell leukaemia 
(94). 
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4D5MOCBETA (VB4-845) is another promising ITs for the treatment of 
solid tumors. It is composed of a humanized scFv fragment (4D5MOCB) specific 
for EpCAM genetically fused to a truncated form of ETA (58). Two formulations 
of this IT have entered clinical trials under the trade names of Proxinium and 
Vicinium (Viventia Biotech). Proxinium is used for the treatment of head and 
neck cancer and Vicinium is used for the treatment of bladder cancer. Phase I 
clinical trials have been completed with Proxinium and to further evaluated the 
safety and efficacy Phase II and III studies have been started. Vicinium has 
completed phase I clinical trials and is undergoing a phase II clinical trial. (57) 
Several ITs that target the Lewis Y antigen, which is highly expressed in 
many epithelial tumors, have also been tested in the clinic (95-96). Mesothelin is 
another TAA which is targeted by ITs, due to its overexpression on 
mesothelioma, ovarian and pancreatic cancer (97).  
Except for some cases (98-99) ETA-based ITs have been mainly 
accomplished with antibody fragments such as scFv and dsFv. For this reason 
they have to be expressed in the periplasm of bacteria or need to be refolded 
after expression in inclusion bodies. These methods result in low protein yields 
or laborious refolding and purification procedures to obtain biologically active 
proteins after renaturation. Since for ITs no other feature of the antibody is 
required than its antigen binding ability, a solution might come from the use of 
alternative non-IgG binding scaffolds as targeting moieties ((100) and Martin 
Killias et al., in preparation). These can be engineered to have the same or even 
better specificity and affinity and to improve production yield and stability. 
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Alternative binding molecules 
 
MAbs offer many attractive features for tumor targeting, as mentioned 
before. However, they suffer from clear limitations especially when merely used 
to deliver a payload: High manufacturing costs, a complex molecular format, 
laborious production and limited efficacy due to their rather large size and low 
tissue penetration. To overcome some of these limitations several antibody 
fragments have been generated such as Fab, scFv and dsFv (101).  Although 
promising, they are still based on the immunoglobulin format and consequently 
they share some of the antibody’s sub-optimal biophysical properties. Over the 
past years several strategies based on different protein topologies than the 
immunoglobulin format have been developed. Ideally, these alternative binding 
molecules should overcome the shortcomings of antibodies while keeping the 
target affinity and specificity (102) 
Numerous alternative binding proteins have been characterized and their 
application in research, diagnostics and therapy are being analyzed (103-104). Of 
these, Designed Ankyrin Repeat Proteins (DARPins) form a particularly promising 
innovative approach. 
 
 
Ankyrin repeat proteins and DARPins 
 
Ankyrin repeat (AR) proteins are natural binding molecules which are 
involved in diverse cellular functions. They have been found across all phyla 
ranging from viruses to humans. The ankyrin repeat has been found in more than 
400 proteins such as cell cycle regulators, cytoskeletal organizers and tumor 
suppressors (105-106). These proteins are present in nucleus and cytoplasm 
indicating that they can adapt to different environments. Ankyrin repeat 
domains (AR) are repeating structural units of 33 amino acids, which stack 
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together to form elongated proteins (107). Structurally, each repeat consists of a 
beta turn followed by two antiparallel alpha helices and a loop reaching the turn 
of the next repeat. The number of repeats within one protein is variable.  
To take advantage of the properties of ankyrin repeat proteins as binding 
molecules, a library was engineered by consensus design (108). In this approach 
six of the 33 amino acids in each consensus repeat were randomized and 
libraries containing 2 or 3 repeats were generated. To shield the hydrophobic 
core a capping repeat was added at each the N and C terminus (Figure 6). 
Members of the libraries are named Designed Ankyrin Repeat Proteins 
(DARPins). This strategy produced not only large libraries but also DARPins with 
optimal biophysical properties (109). These libraries are a valuable source of 
binding molecules, which was shown by selection of high affinity binders against 
several types of proteins (110-113). The simple molecular and modular 
architecture of DARPins allows a broad range of applications. This, taken 
together with their high affinity and selectivity makes DARPins attractive 
candidates for further drug development.  
 
 
Figure 6. Schematic representation of the DARPin library (114). In green the N-
terminal capping repeat, follow by a variable number of internal repeats in blue 
and in cyan the C-terminal capping repeat. Randomized amino acid side chains 
are depicted in red.  
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DARPins in targeted cancer therapies 
 
DARPins have been selected against several TAAs such as HER2 (113, 
115), EGFR, ErbB4 (116) and EpCAM (Martin Killias et al., in preparation) using 
both ribosome display and phage display. Due to their high affinity, specificity, 
easy production process, small size and robustness, they can be consider as ideal 
molecules for targeted therapies. Several molecular formats might be possible 
using DARPins (117) which opens the door to different therapeutic applications. 
DARPins can be employed as monovalent or bivalent binders, in a bispecific 
construct, or conjugated to various effector molecules. As examples, Her2-
specific DARPins were successfully used in situ for staining of sections of breast 
carcinoma (115), and bivalent Her2-DARPins are currently being investigated as 
potential therapeutic agents with very promising results in vitro (Tamaskovic, 
personal communication). In addition, EGFR-specific DARPins were able to inhibit 
cell proliferation of EGFR-positive cells (Boersma et al., in preparation). EpCAM-
specific DARPins fused to protamin were successfully used to deliver siRNA to 
tumor cells (118) and a EpCAM-DARPin fused to ETA have shown potent 
antitumor activity on tumor xenografts (Martin Killias et al, in preparation). All 
these data warrant the further development of DARPins toward future clinical 
applications.  
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Aim of the thesis 
 
This thesis describes the generation of a novel system for the delivery of a 
truncated form of Pseudomonas exotoxin A (ETA") to tumor cells. An EpCAM-
specific DARPin, fused to the toxin, is used as the targeting moiety. The rationale 
for this approach is to take advantage of the favorable characteristics of DARPins 
as a targeting moiety in conjunction with the favorable properties of EpCAM as a 
tumor marker. 
The first goal was to select DARPins specifically recognizing EpCAM with 
high affinity. To this purpose, the extracellular domain of EpCAM was produced, 
purified and used as a target for selection. DARPins were selected with a novel 
phage display system, SRP phage display, a system adapted for highly stable and 
fast folding proteins. As an alternative approach, ribosome display and affinity 
maturation procedures were performed. Using both selection systems, several 
EpCAM-specific DARPins were selected and characterized. 
The second part of the project was to asses the potential of EpCAM-
specific DARPins for tumor targeting and delivery of ETA". To this end, one of the 
characterized DARPins, Ec4, was genetically fused to ETA" to generate the first 
EpCAM-specific DARPin-toxin, Ec4-ETA". This DARPin-toxin fusion protein was 
biochemically characterized and its cytotoxicity and antitumor activity were 
evaluated both in vitro and in vivo. 
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Abstract 
 
 
Designed Ankyrin Repeat Proteins (DARPins) represent a novel class of 
binding molecules. Their very favorable biophysical properties such as high 
affinity, stability and expression yields make them ideal candidates for tumor 
targeting. Here, we describe the selection of DARPins specific for the tumor-
associated antigen epithelial cell adhesion molecule (EpCAM), a relevant target 
for cancer therapies. Several DARPins were selected from combinatorial libraries 
by phage display and ribosome display. The first generation of EPCAM binders 
was then further improved. The resulting second generation of DARPins were 
expressed at high yields and specifically bound to EpCAM-expressing cells. One of 
the binders, denoted Ec4, bound to EpCAM with picomolar affinity (Kd=917.2 ± 
77.8 pM). In addition, it was internalized upon receptor binding, an important 
prerequisite for delivery of cytotoxic agents to the tumor. Taken together, the 
results indicate that EpCAM-specific DARPins could be of key interest as an 
alternative to antibodies for tumor targeting. 
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Introduction 
 
The epithelial cell adhesion molecule (EpCAM) is a tumor-associated 
antigen which is overexpressed in many solid tumors (1-3) and was recently 
identified as a cancer stem cell marker (4-5). Whereas EpCAM was initially 
considered to be a homophilic cell-cell adhesion molecule, more recent studies 
demonstrated its role as an oncogenic signaling molecule, which is activated via 
regulated intramembrane proteolysis, with the cleaved cytoplasmic domain 
driving the expression of the proto-oncogen c-myc and the cell cycle regulators 
cyclin A and cyclin E (6-7). Moreover, there is evidence that EpCAM interacts with 
a number of metastasis associated proteins in the cell membrane, such us CD44, 
tetraspanins and claudin 7 (8-9).  
The high level of EpCAM in solid tumors and its limited expression in 
normal epithelial tissues (10), whose basolateral expression moreover render it 
poorly accessible, makes it attractive for tumor-targeting (11-13). In previous 
work we generated an EpCAM-specific immunotoxin from a stability engineered 
anti-EpCAM scFv fused to truncated Pseudomonas exotoxin A (14), which is 
currently in phase II clinical investigation for the treatment of non-invasive 
bladder cancer (15). In addition, we have developed EpCAM-targeted nanoscale 
delivery systems which were loaded with therapeutic antisense oligonucleotides 
or doxorubicin, and which were tumor-targeted by the same scFv antibody (16-
17). Since the production process for the recombinant antibody fragments, 
especially in conjunction with drug delivery systems is still demanding, 
alternative binding molecules, such as more stable and better expressing non-IgG 
scaffold proteins might be advantageous (18). This will especially allow to 
construct formats which are not accessible at all for scFv derived constructs. 
Designed Ankyrin Repeat Proteins (DARPins) are well-suited for this 
purpose, since they show favorable biophysical properties, such as high 
expression yield and low aggregation tendency (19-22). Their stable and flexible 
structure, small molecular weight (14 to 21 KDa) and ease of production make 
them suitable tools for biomedical applications. Moreover, the absence of 
cysteines allows site-specific modification and conjugation with various effector 
moieties. The ankyrin repeat is built from two antiparallel helices and a loop 
extending in perpendicular direction, and potential interaction residues were 
  
48 
randomized, while residues important for maintaining the repeat structure 
(framework) were defined and kept constant in a consensus design approach. 
DARPin libraries with different numbers of repeats (two or three) were 
assembled in between N- and C-terminal capping repeats, shielding the 
hydrophobic core (19). Recently, the C-terminal repeat was redesigned to further 
improve the stability of these proteins (23).  
High affinity binders against several target proteins have been isolated 
from DARPin libraries mostly using ribosome display (20-22). Ribosome display is 
performed entirely in vitro (24-25) and in combination with error-prone PCR 
constitutes an ideal tool for affinity maturation of binding proteins, since 
mutations can be easily introduced after each selection round (26). Phage display 
was also used to select DARPins from libraries, but the standard filamentous 
phage system had to be modified for the display of these proteins rapidly folding 
already in the cytoplasm. By using a signal sequence targeting the signal 
recognition particle (SRP) dependent pathway (27), co-translational transport is 
achieved, and such a DARPin phage library was successfully used to efficiently 
select binders against a wide range of targets (28).  
Binding proteins destined for therapeutic applications need to fulfill many 
stringent criteria, and a wide range of targeted epitopes is thus useful initially. It 
was therefore of interest to select with ribosome display and phage display in 
parallel. Indeed we found different binders from both methods, which we can 
partially rationalize. Moreover, we could by subsequent evolutionary rounds of 
ribosome display not only improve affinities to the picomolar range but also 
improve the biophysical properties of the evolved binders. We characterized the 
evolved binders on cells and some DARPins were analyzed for internalization 
upon binding as an important prerequisite for efficient delivery of cytotoxic 
compounds to target cells. 
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Material and Methods 
 
Cell lines and culture condition. 
The colorectal carcinoma cell line HT29, the breast adenocarcinoma cell 
line MCF7, the non-Hodgkin's lymphoma cell line RL, the squamous cell 
carcinoma cell line of the tongue CAL27, the prostate carcinoma cell line LNCAP 
and the human embryonic kidney cells HEK293T were obtained from ATCC 
(American Type Culture Collection). The small cell lung carcinoma cell line SW2 
was maintained in our laboratory for many years. All cell lines were grown in 
DMEM (Dulbeccos's modified Eagle's medium) (Sigma, Buchs, Switzerland). 
Culture medium was supplemented with 10% heat inactivated fetal bovine 
serum (Amimed, Bioconcept, Allschwil, Switzerland), 100 IU/ml penicillin and 100 
μg/ml streptomycin (Sigma). Cell cultures were maintained at 37°C in a 
humidified atmosphere containing 5% CO2. All cells were tested negative for 
mycoplasma using MycoAlert (Lonza, Basel, Switzerland ). 
 
EpCAM expression and purification. 
The cDNA encoding EpCAM was kindly provided by Dr. M. Münz 
(Micromet AG, Munich, Germany). The extracellular domain of EpCAM (EpEx), 
residues 1 to 265 (including the signal sequence), was cloned into the plasmid 
pCDNA3.1(-) for mammalian cell expression. Two additional tags were added to 
the C-terminus of the protein, an Avi-tag (GLNDIFEAQKIEWHE) for biotinylation 
followed by a His6 tag for protein detection and purification. The expression 
vector was transiently transfected into HEK293T cells using the standard calcium 
precipitation protocol. Four days after transfection, cell culture media was 
collected, centrifuged and filtrated to eliminate cell debris.  
The supernatant containing EpEx was concentrated and loaded on a Ni-
NTA column packed with Ni-NTA superflow (Qiagen, Hilden, Germany). After 
washing with 5 column volumes (50 mM NaH2PO4 pH 8.0, 500 mM NaCl, 10% 
glycerol and 10 mM imidazole), EpEx was eluted with elution buffer (50 mM 
NaH2PO4, pH 8.0, 300 mM NaCl, 10% glycerol and 250 mM imidazole). After 
purification, EpEx was dialyzed against 10 mM tris and enzymatically 
biotinylated. One mg of protein (at a concentration of 1 mg/ml) was incubated 
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with 10 µg of BirA (Avidity, Aurora/Colorado, USA) at room temperature 
overnight in a buffer containing 50 mM bicine pH 8.3, 10 mM ATP, 10 mM 
Mg(CH3COO
–)2 and 40 µM biotin. Biotinylated EpEx (bEpEx) was dialyzed against 
PBS (15 mM KH2PO4, pH 7.4, 81 mM Na2HPO4, 27 nM KCl, 137 mM NaCl) to 
remove unreacted biotin. Efficient biotinylation was confirmed by using ELISA 
and western blotting and detection with a streptavidin- horseradish peroxidase 
conjugate as detection reagent (Roche, Basel, Switzerland). 
 
Selection of DARPins by SRP phage display and epitope masking 
The selection of EpCAM-specific DARPins by phage display was performed 
essentially as previously described (29). For the first selection round on 
immobilized target protein, 66 nM neutravidin (Pierce, Rockford, USA) was 
coated on MaxiSorp immunotubes (Nunc, Roskilde, Denmark). Tubes were 
blocked with PBSTB (PBS, 0.1% Tween-20, 0.2% BSA) for 1 h and bEpEx (1 ml, 400 
nM) was added for 2 h at 4°C. The second and third rounds were performed on 
MaxiSorp plates (Nunc). Neutravidin (Pierce) or streptavidin (Sigma) were coated 
to the plates (66 nM, 100 µl/well in PBS) at 4°C overnight. After washing, bEpEx 
(100 nM, 100 µl/well) was added for 1 h at 4°C. To avoid selection of binders 
against neutravidin or streptavidin, these two proteins were used alternately in 
subsequent rounds. At the end of the third round, enrichment of specific binders 
was monitored by phage ELISA. 
 For epitope masking, Eph1 was expressed in E. coli and purified by IMAC 
as described below (purification of DARPins). Pools of phage particles after the 
first round on immobilized protein (in tubes) were used as input material. bEpEx 
(100 nM) was incubated with EPh1 (10 µM) for 1 h before a standard selection 
round on soluble protein was performed, where complexes of phages bound to 
bEpEx were captured with streptavidin-coated paramagnetic beads (Dybabeads 
MyOne Streptavidin T1, Dynal, Invitrogen, San Diego, USA) for 20 min. After 
three rounds of selection with epitope masking, phage enrichment was analyzed 
by phage ELISA in the presence or in the absence of an excess of EPh1. 
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Phage ELISA 
Phage ELISA was performed to detect specific enrichment of phages 
against EpCAM. Neutravidin (66 nM), Streptavidin (66 nM) and human IgG1 Fc 
domain (100 nM) were directly coated to MaxiSorp plates (Nunc) overnight at 
4°C. Biotinylated proteins, bEpEx (100 nM) and ErbB4 (100 nM), were coated via 
neutravidin for one hour at 4°C. Output phages from each round (~1·105 phages) 
were incubated with the target and control proteins for 2 h at room 
temperature. After 3 washes with PBST (PBS, 0.1% Tween-20), bound phages 
were detected with mouse anti-M13 antibody horseradish peroxidase conjugate 
(Glattbrugg/Zürich, Switzerland).  
 
Selection of DARPins by ribosome display 
Both N2C and N3C DARPin libraries (19) were used to select for DARPins 
binding to EpEx. Three rounds of selection by ribosome display were performed 
essentially as described before (25). Briefly, for each round the translation mix 
containing mRNA-ribosome-DARPin complexes was incubated for 1 h at 4°C with 
100 nM bEpEx in solution. The complexes bound to EpCAM were captured 
incubating with 100 µl streptavidin-coated paramagnetic beads (Dynabeads 
MyOne Streptavidin) for 30 min at 4°C. After washing the beads with WBT (50 
mM Tris acetate, pH 7.6, 150 mM NaCl , 50 mM Mg(CH3COO
–)2, 0.01% Tween-
20), the mRNA was eluted with elution buffer (50 mM Tris acetate, pH 7.6, 150 
mM NaCl, 250 mM EDTA) and prepared for another round of selection. To 
minimize selection of unspecific binders, all tubes were pretreated with TBST (50 
mM Tris acetate, pH 7.6, 150 mM NaCl, 0.05% Tween-20) supplemented with 
0.1% of BSA. To further avoid binders against the streptavidin present on the 
paramagnetic beads, before each panning step, the translational mix was 
preincubated with the beads for 1 h at 4°C. 
 
Affinity maturation 
Selection of second generation binders was performed as described (25-
26) with a few modifications. First, EpCAM-specific DARPins selected by phage 
display or ribosome display, were randomly mutated by error-prone PCR. Each 
DARPin was amplified individually in the presence of 3, 9 and 20 µM dNTP 
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analogues dPTP (6-(deoxy-β-D-erythro-pentofuranosyl)-3,4-dihydro-8H-
pyrimido-[4,5-c][1,2]oxazine-7-one-5'-triphosphate) and 8-oxo-dGTP (8-oxo-2'-
deoxyguanosine-5'-triphosphate). Each amplification was performed in a 50 μl 
reaction in the presence of 1 μM primers, one unit of PlatinumTaq DNA 
Polymerase (Invitrogen), 5% DMSO, 1.5 mM MgCl2 and 200 μM dNTPs. PCR 
products were then pooled in equimolar amounts for selection experiments. 
 Four rounds of ribosome display were performed. In rounds 1 and 3, the 
translation mix was incubated for 1 h at 4°C with 0.7 µM bEpEx and subsequently 
a 5000-fold excess of non-biotinylated EpEx was added (30). This mixture was 
kept under slow shaking at 4°C for 2 or 10 h, respectively, to select for binders 
with a slow off-rate. In rounds 2 and 4, 100 nM bEpEx were used in the panning 
step and no non-biotinylated competitor was added to enrich correct clones 
without further selection pressure. mRNAs of complexes bound to bEpEx were 
isolated as described above. 
 
Purification of DARPins 
Selected DARPins from phage and ribosome display were cloned into a 
pQE30-derived vector (Qiagen, Hilden, Germany), containing an N-terminal 
MRGS(H)6 tag and a C-terminal double stop codon (pQE30ss) or into 
pQE30_sfGFP, the latter to create DARPins C-terminally fused to superfolder GFP 
(31). For ELISAs, affinity measurements, labeling and flow cytometry DARPins 
were produced in soluble form in E. coli XL1-blue (Stratagene, La Jolla, USA) and 
purified using Ni-NTA Superflow (Qiagen) in gravity flow columns as described 
(19). For SPR measurements, the proteins were further purified by preparative 
size exclusion chromatography.  
 
Size Exclusion Chromatography 
DARPins (15 µM) in 50 µL PBS were analyzed on a Superdex-200 PC 
3.2/30 column using either an ETTAN or ÄKTAmicro chromatography system (all 
GE Healthcare) at a flow rate of 60 µl/min and with PBS as running buffer. For 
preparative size exclusion chromatography, DARPins were purified on a 
Superdex-200 10/300 GL column using an ÄKTAexplorer chromatography system 
(GE Healthcare) at a flow rate of 1 ml/min. 
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ELISAs 
MaxiSorp plates were coated with 100 µl of 66 nM neutravidin in PBS 
overnight at 4°C. After washing, all wells were blocked with 300 µl PBS 
containing 0.2 % of bovine serum albumin (BSA) for 1 h at room temperature. 
Protein targets were biotinylated and added to the wells to a final concentration 
of 50 nM (10 nM in competition ELISAs). Crude bacterial extract (100 µl, for 
screening of single clones from phage display and ribosome display selections) or 
purified DARPins (100 µl, 200 nM for specificity and 10 nM in competition ELISAs) 
were added at room temperature. After 1 h, bound DARPins were detected with 
an anti RGS-His6 antibody conjugated with horseradish peroxidase (Qiagen) or 
with an anti-RGS-His6 antibody (Qiagen) and an anti-mouse-IgG conjugated to 
alkaline phosphatase (Pierce). For the competition ELISA, the same setup as 
described above was used except that purified DARPins were incubated with 100 
nM non-biotinylated EpEx prior to incubation with immobilized EpCAM for 10 
min at room temperature. 
 
Labeling of DARPins with AlexaFluor-488 
EpCAM-specific DARPins as well as control DARPins were cloned into a 
pQE30-based vector, appending two glycines and a cysteine. These DARPins 
containing a unique cysteine at their C-terminus were expressed and purified as 
described above. Cys-DARPins were fully reduced by incubation with 100-fold 
excess of tris-(2-carboxyethyl)phosphine (TCEP) for 30 min at 37°C in PBS pH 7.4. 
TCEP removal and buffer exchange to degassed PBS pH 7.1 was achieved with a 
HiTrap desalting column (GE Healthcare). AlexaFluor488-C5-maleimide 
(Invitrogen) was added in 2-fold excess and incubated at 25°C for 2 h. After 
quenching unreacted dye with 10 mM dithiothreitol (DTT) for 20 min at 25°C, a 
PD-10 column (GE Healthcare) was used to remove unreacted dye and exchange 
the buffer to 100 nM sodium-bicarbonate with 20 nM NaCl, pH 8. Monolabeled 
DARPin was separated from unlabeled protein by anion exchange 
chromatography on a MonoQ 5/50 GL column (GE Healthcare) using 100 nM 
sodium bicarbonate with 1 M NaCl at pH 8 for isocratic elution. 
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Flow cytometry analysis. 
Flow cytometry analysis was performed to confirm the binding of 
DARPins to EpCAM expressed on the surface of a variety of tumor cell lines. 1·106 
cells were harvested and washed two times with PBS, then resuspended in FACS 
buffer (PBS, 1% BSA) containing the DARPin (fused to GFP, coupled to Alexa488 
or unlabeled) (100 nM) and incubated for 45 minutes on ice. Unlabeled DARPins 
were detected using anti-RGS-His antibody (Qiagen) and a goat anti-mouse FITC 
labeled secondary antibody (Invitrogen). Cells were washed three times between 
all incubation steps with FACS buffer. After the last wash, cell were resuspended 
in 1 ml FACS buffer and subjected to flow cytometry using a FACSCalibur or 
FACSCanto II flow cytometer (both BD Bioscience). For each experiment 10,000 
cells were counted. Data were analyzed using the FlowJo software (Tree Star, 
Ashland/Oregon, USA) 
 For competition experiments with unlabeled DARPins, 500,000 HT29 cells 
were incubated with 100 nM Ec4-sfGFP or Ac2-sfGFP fusion proteins or the 
monoclonal anti-EpCAM antibody MOC-31 for 30 min on ice. For competition, 
the cells were preincubated with 10 µM DARPins Ec4 or Ac2 for 15 min on ice. 
MOC-31 treated samples were additionally incubated with 2 µg/ml Alexa Fluor® 
488 goat anti-mouse IgG (Invitrogen) for 20 min on ice. Cells were then analyzed 
by flow cytometry as described above. 
 
Affinity determination 
Affinity determination on cells. Harvested MCF-7 cells were pre-incubated 
for 30 min at 37°C in FACS buffer supplemented with 0.2% sodium azide to 
inhibit internalization. For equilibrium experiments, 3·105 cells in 500 µl were 
incubated for 1 h at 4°C with different concentrations of DARPin-sfGFP ranging 
from 100 pM to 200 nM. After one washing step, mean fluorescence intensities 
(MFIs) were measured on a FACSCanto II flow cytometer (BD Bioscience). For 
dissociation rate experiments, 3·105 cells were saturated for 1 h at 4°C with 100 
nM DARPin-sfGFP. Then, the cells were centrifuged (300 g, 3 min, 4°C) and 
resuspended with 1 µM DARPin as an unlabeled competitor to prevent 
rebinding. MFIs were recorded at different time points between 0 to 4 h. For 
association rate  experiments, 3·105 cells were incubated with 2.5, 7.5 or 22.5 
nM DARPin-sfGFP and measured at times between 1 and 60 min without prior 
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washing. Background association of an unselected library member E3_5 fused to 
sfGFP was subtracted. Data evaluation was performed with Prism (GraphPad). 
 
Affinity determination with surface plasmon resonance. All measurements 
were performed on a Biacore 3000 instrument. A streptavidin (SA) chip was 
prepared according to the manufacturer’s protocol and was coated with bEpEx 
to about 120 resonance units. DARPins ranging from 1 to 100 nM were injected 
at a buffer flow of 30 µl/min in HBST (20 mM Hepes, pH 7.4, 150 mM NaCl, 
0.05% Tween-20). Data evaluation was performed using BIAEVAL (Biacore) or 
Scrubber 2 (Biologic Software). 
 
Internalization by Confocal microscopy 
MCF-7 cells (2·105  cells) were seeded on coverslips and incubated for 24 
h at 37°C and 5% CO2. EpCAM-specific DARPins, EPh1, and the unspecific DARPin 
off7 labeled at an engineered C-terminal cysteine (see above) with AlexaFluor-
488 (AlexaF488) were added to the cells at a final concentration of 100 nM 
(diluted in DMEM). After 1 hour of incubation at 37°C or at 4°C with the labeled 
DARPins the cells were washed three times with PBS for 5 minutes each time and 
fixed with 4% paraformaldehyde in PBS (10 minutes at room temperature). 
Thereafter the cells were rinsed with PBS and the nuclei were stained with 0.8 
μg/ml 4',6-diamidino 2-phenylindole (DAPI) in PBS for 2 min. The coverslips were 
then quickly washed with PBS, mounted in glass slides with Fluoromount G 
(Southern Biotech) and sealed with nail polish. The glass slides were kept in the 
dark at 4°C until confocal microscopy was done. Fluorescent images were 
recorded using a confocal laser scanning microscope (TCS-SP 2, Leica Mannheim, 
Germany) with a selected confocal plane approximately in the middle of the cell. 
Images were processed using Imaris 3D software (Bitplane). 
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Results 
Selection of EpCAM-specific DARPins using SRP phage display 
 
To maximize the chances of covering different epitopes on EpCAM, 
DARPins were selected both with SRP phage display (27-28) and ribosome display 
(see below). Three rounds of SRP phage selection were performed using the 
biotinylated extracellular domain of human EpCAM (bEpEx) immobilized to, 
alternately, neutravidin or streptavidin, itself bound to a solid plastic surface. The 
phage display library is in the N3C format. Specific EpCAM enrichment was 
already observed in the second round (Figure 1A), but it was notably stronger 
after the third round. Individual DARPins selected in the third round were 
screened for specific EpCAM binding by crude extract ELISA. DNA sequencing of 
20 clones revealed one dominant clone, named EPh1. This binder contained a 
deletion of two amino acids between the N-terminal capping repeat and the first 
internal repeat. This deletion seemed to be important for EpCAM binding, since 
mutants were the deletion was corrected, showed reduced affinity to EpCAM 
when tested by ELISA (data not shown). Epitope masking. To increase the 
diversity and select DARPins binding to different EpCAM epitopes, we used an 
epitope masking strategy (32). The dominant binder obtained by the initial 
selection step, EPh1, was expressed, purified and added to new selection rounds 
in 100-fold excess to block the dominant epitope and to focus the selection 
against other epitopes. Since immobilization of the antigen can mask potential 
binding epitopes, the new selection rounds were performed in solution. The 
output from the first selection round on immobilized target formed the starting 
material for another four rounds of panning in solution. Output phages from 
round 3em and 4em (em: epitope masking) were analyzed by phage ELISA for 
binding to EpCAM in the presence and absence of the dominant binder EPh1 
(Figure 1B) suggesting that some of the newly selected DARPins recognized 
different epitopes than EPh1. Individual DARPins from round 4em were analyzed 
by crude extract ELISA (Figure 1C) and 20 binders were sequenced. The results 
revealed 5 new EpCAM binders, termed EPh2 to Eph6 
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Figure 1. Phage display selection. A) Enrichment of EpCAM binders by phage 
ELISA. BSA, Streptavidin, Neutravidin, EpCAM, ErbB4 or human IgG1 Fc were 
immobilized on a plate and equal amounts of the initial phage library or of the 
output phages after each round (R1, R2 and R3) were added to the plate. The 
bound phages were detected using an anti M13 antibody horseradish peroxidase 
(HRP) conjugate. B) Enrichment of EpCAM binders after epitope masking by 
phage ELISA. As describe in fig 1A, specific enrichment of phages from round 
3em and 4em (epitope masking) was analyzed. In addition, enrichment of phages 
against EpCAM was tested in the presence of an excess of the blocking agent 
EPh1 (EpCAM + EPh1). Biotinylated EPh1 was coated to the plates to test for 
enrichment against the blocking agent.  
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Figure 1 C) ELISA screening of single clones. E.coli extracts of randomly picked 
clones expressing DARPins of selection round 4em (epitope masking) were 
analyzed for specific binding to EpCAM and to streptavidin.  
 
 
Expression, purification and specificity of the selected DARPins 
 
The selected DARPins, including EPh1 with the small deletion, were 
expressed at high levels in soluble form in the cytoplasm of E. coli XL1-Blue (up to 
140 mg/L). All proteins were purified by a single immobilized metal affinity 
chromatography (IMAC) purification step (Figure 2A). The specificity of the 
selected DARPins was determined by ELISA (Figure 2B). E3_5 (33), an unselected 
member of the DARPin library, served as a control and showed no binding to 
EpCAM or any of the control proteins. 
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Figure 2. A) SDS-PAGE analysis of DARPin purification. A representative EpCAM-
specific binder was purified by one-step Immobilized Metal Affinity 
Chromatography (IMAC). Fractions from purification were visualized by 
Coomassie blue. Lanes: M, molecular weight marker (indicated in kDa); P, 
bacterial pellet; S, supernatant from cell lysate; FT, Flow-through from IMAC 
column; Elutions, eluted fractions from IMAC. B) Binding specificities of selected 
DARPins. The 6 selected DARPins were purified and tested in ELISA for binding to 
EpCAM, neutravidin, ErbB4, MBP (maltose binding protein) and to EGFR 
(epidermal growth factor receptor). As further controls, an unselected member 
of the library (E3/5) and the background binding of the detection antibodies are 
shown in the absence of any DARPin (No DARPin). 
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EpCAM binding of the selected DARPins on the cells and EPh1 
epitope characterization. 
 
We then investigated whether the selected binders were able to bind to 
the antigen on the cell surface as well. To this end, the DARPins were genetically 
fused to superfolder green fluorescent protein (sfGFP)(31), and analyzed for 
binding to the EpCAM-positive MCF-7 (breast adenocarcinoma) tumor cell line 
using flow cytometry. DARPin_sfGFP fusion proteins expressed very well and 
showed EpCAM-specific binding in ELISA (Figure 3A) and maintain their 
fluorescence. For antibody fragments, such direct GFP fusions can only be 
produced with very low yields (34). To assess whether GFP would interfere with 
or unspecifically contribute to binding of the DARPins to EpCAM on the surface 
of viable cells, we used two additional detection methods: (i) unfused DARPins 
were incubated with target cells and detected with a primary (anti His-tag, 
located at the N-terminus) and a secondary FITC-labeled antibody using flow 
cytometry and (ii) EpCAM binders were cloned in a vector containing a C-
terminal AviTag for in vivo biotinylation. The biotinylated binders were 
expressed, purified and incubated with streptavidin Alexa Fluor 488.  
Flow cytometry indicated the same result for all three detection methods 
(Figure 3B): while all selected DARPins showed specific binding to EpCAM in 
ELISA, only one, EPh1, was able to bind to EpCAM in its native conformation on 
the cell surface of the MCF-7 cells. This was observed in all three approaches. 
This indicates the validity of the measurements with DARPin-GFP fusions. 
DARPins that did not bind to native EpCAM on the cell membrane were not 
further studied. Their appearance suggests that epitopes were exposed by the 
purified EpCAM which are hidden in the protein on the cell surface. 
To confirm that EPh1 binds to EpCAM on various tumor cell types and 
thus would be suited for EpCAM-specific tumor targeting, we investigated its 
binding to four other EpCAM-positive cell lines of different histological origin 
(CAL 27 tongue squamous cell carcinoma, SW2 small cell lung cancer, LNCAP 
prostate carcinoma and HT29 colorectal adenocarcinoma) using flow cytometry. 
As shown in Figure 3C, EPh1 bound to all EpCAM-positive cell lines, while no 
binding was measured on the EpCAM-negative cell line RL (non-Hodgkin's 
lymphoma). 
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We compared the EPh1 epitope with that of the well-characterized 
monoclonal antibody Moc31, which recognizes an epitope present on the 
extracellular EGF-like domain of EpCAM (35). EPh1-specific binding to EpCAM 
was reduced in the presence of Moc31 in both ELISA and flow cytometry (Figure 
3D), indicating that EPh1 and Moc31 bind to an at least partially overlapping 
epitope. As a further control, it was shown that soluble EpEx could compete the 
specific binding to immobilized bEpEx in ELISA. 
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Figure 3. A) ELISA of EpCAM-specific binders fused to sfGFP. DARPins fused to 
superfolder GFP (sfGFP) were analyzed for EpCAM binding on ELISA. Biotinylated 
EpCAM (20 nM) was immobilized on neutravidin coated plates. Binding of 
DARPins_sfGFP was detected using a mouse anti-RGS(His)4 as primary and 
alkaline phosphatase-coupled goat anti-mouse IgG as secondary antibody. 
E3_5_sfGFP, an unselected member of the library, is shown as a negative control. 
B) Flow cytometry analysis of MCF-7 cells with, EPh1_sfGFP, EPh1Avi and 
untagged Eph1. EPh1_sfGFP; EPh1Avi_strepAF488 (streptavidin_AlexaFluor488); 
and untagged EPh1 or as control an unselected member of the library E3_5 
(E3_5sfGFP, E3_5Avi_strepAF88 and untagged E3_5) were incubated with MCF-7 
cells for 45 minutes at 4°C. Untagged EPh1 and E3_5 were detected with anti- 
(His)4 primary antibody and anti mouse FITC labeled secondary antibody. Cells 
were analyzed by flow cytometry. Red: autofluorescence of MCF-7 cells, green: 
E3_5_sfGFP, orange: E3_51Avi_strepAF488, blue: untagged E3_5, tinted green: 
EPh1_sfGFP, tinted orange: EpH1_Avi_strepAF488, tinted blue: untagged EpH1. 
C) Binding of EPh1 to different tumor cell lines analyzed by flow cytometry. 
EPh1 fused to sfGFP was incubated for 45 min at 4°C with different EpCAM 
positive carcinoma cell lines (CAL 27, HT29, MCF7, SW2, and LNCAP). The EpCAM 
negative cell line RL was used as control. Fluorescence signals from EPh1_sfGFP 
are shown in black, autofluorescence of cells in grey. D) ELISA_ MOC31 
competition. Binding of EPh1 to immobilized EpCAM was competed with the 
monoclonal antibody Moc31 and with soluble non biotinylated EpCAM. 
Biotinylated EpCAM (20 nM) was immobilized on neutravidin coated plates. 
Binding of EPh1 (10 nM) was detected. Competition with a 10 fold excess of 
Moc31 (100 nM) or with soluble EpCAM (100nM) was examined. Moc31 (100 
nM) binding to bEpEx is included as positive control. Binding of EPh1 to 
Neutravidin is shown as background control. Flow cytometry_ MOC31 
competition. Binding of EPh1 to CAL27 cells was competed with the monoclonal 
antibody Moc31. CAL27 cells (1. 106 cells) were incubated with EPh1_sfGFP alone 
(green) or in the presence of an excess of the monoclonal antibody Moc31 
(blue). Cells autofluorescence is shown in red. 
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Internalization by confocal microscopy 
 
Since our strategy is to use DARPins for targeted delivery of cancer 
therapeutics to solid tumors, we explored if EPh1, the first generation molecule, 
is efficiently internalized upon binding to EpCAM on the cell surface. Therefore, 
EPh1 was labeled with Alexa Fluor 488 and added to MCF-7 tumor cells at 37°C 
(to allow receptor internalization) or at 4°C (to prevent internalization). Cells 
were observed using a confocal microscope to monitor subcellular localization of 
the DARPin (Figure 4). The staining pattern obtained at 4°C showed 
predominantly diffuse surface membrane fluorescence, whereas at 37°C the 
bright punctuated dots represented internalized DARPin, which was probably 
localized in endo-/lysosomes. 
 
 
 
 
 
 
 
 
Figure 4. EPh1 internalization by confocal microscopy. The EpCAM-positive cell 
line MCF-7 was treated with fluorescent labeled EPh1 at 37°C or 4°C. After 1 hour 
incubation, cells were washed, fixed with 4% PFA, and then imaged using a 
confocal scanning fluorescence microscope. Nuclei were counterstained with 
DAPI. The images were produced with a selected confocal plane in the 
approximated middle of the cells. Images were processed using Imaris 3D 
software 
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Selection of EpCAM-specific DARPins using ribosome display 
 
To increase our range of binders, two different DARPin libraries (N2C and 
N3C) (19) were also used in ribosome display. Three selection rounds in solution 
were performed and DARPins obtained after the third round of selection were 
analyzed for specific binding to bEpEx by crude extract ELISA and we identified 
seven EpCAM binders which belong to three distinct families, defined by having 
the same or almost the same randomized positions but different framework 
mutations. All sequences differed at the randomized positions from EPh1. The 
newly selected DARPins were fused to sfGFP and analyzed for binding to EpCAM 
by flow cytometry. All analyzed DARPins showed binding to EpCAM-positive but 
not to EpCAM-negative cells (data not shown). While it is tempting to speculate 
that the greater size of the ribosome display library, and the inherent 
diversification by random mutations in the ribosome display process, contributed 
to the larger number of cell-binding clones, it is also possible that epitope 
masking employed in phage display significantly restricted the accessible space. 
Also, the ribosome display selection was carried out in solution, perhaps better 
preserving native epitopes and not exposing new ones. 
The mean fluorescence intensity (MFI), measured by FACS, of the newly 
selected DARPins was lower when compared to the MFI of EPh1 (all tested at the 
same concentration) (data not shown). This difference could be due to lower 
functional affinities to EpCAM, either intrinsic, or cause by different 
accessibilities of the epitopes recognized. 
 
 
Affinity maturation 
 
EPh1 and the previously ribosome display selected binders were then 
subjected to affinity maturation by using error-prone DNA polymerase in the 
presence of dNTP analogs (36) followed by new rounds of selection using 
ribosome display. 
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The binders initially selected from ribosome display were in the mid-
nanomolar range as estimated from competition ELISA (37) and data not shown, 
and their affinity needed therefore to be increased. In contrast, EPh1 showed 
much higher affinity already, but it gave rise to formation of dimers or 
multimers. We obtained evidence (see below) that this was not due to any 
instability of the molecule, but most likely to fortuitous self-complementarity of 
its surface. We were therefore interested in whether this self-complementarity 
could also be removed by directed evolution. 
For this purpose, we first replaced the C-cap of all EpCAM binders with a 
more stable version that was recently designed (23). After error-prone PCR, the 
pools were subjected to four or five rounds of selection by ribosome display 
using a combination of stringent and non-stringent rounds (30). On the basis of 
crude extract ELISA signals and SDS PAGE analysis, 92 clones were sequenced, 
resulting in 65 unique sequences. Sequence analysis revealed that thirty 
sequences (46%) were derived from EPh1: this group of binders maintained the 
same randomized positions and the characteristic two amino acid deletion as 
EPh1, but had different framework mutations. The rest of the affinity matured 
binders (33 sequences or 51%) were derived from different binders that had 
come from the original ribosome display selection. Two binders could not be 
assigned to any family of input binders.  
All 65 affinity-matured binders were expressed and purified in 96-well 
format. Based on competition ELISAs, analytical size exclusion chromatography 
and flow cytometry analysis we chose the six best EpCAM binders. Four binders 
belonged to the EPh1 family and were named Ec1 to 4, the other two binders 
were derived from a binder selected by the original ribosome display selection 
and were named Ac1 and Ac2. 
 
 
  
67 
Characterization of the evolved final six EpCAM binders 
 
Binding to EpCAM was tested by competition ELISA; consistent with 
specific binding, the signal in ELISA was decreased for all six binders when non-
biotinylated EpCAM was used as competitor (Figure 5A).  
The proteins were analyzed by gel filtration. Ac1 and Ac2 were 
predominantly monomeric but showed a small shoulder that might correspond 
to a small amount of dimer (Figure 5B), but no aggregation was found. Ec1 to 4, 
derived from EPh1, were entirely monomeric, with no indication of any other 
species.  
The ribosome display, intended for affinity maturation, therefore indeed 
increased the affinity, but also removed the dimerization and oligomerization 
tendency of EPh1. We therefore wished to understand the mechanism of this 
favorable selection outcome. EPh1 contains a two amino-acid deletion, needed 
for recognizing its cognate epitope, but the deletion is in the hairpin loop 
connecting the N-cap with the first internal repeat and can be perfectly 
accommodated in the structure. We analyzed the modeled structure by ROSETTA  
(38), but found no evidence for any unfavorable interactions by this deletion, and 
the expression level of this DARPin (140 mg/l) is in the range of normal DARPins. 
We then investigated all mutations that were selected in ribosome display, but 
there were none that were strongly stabilizing according to the ROSETTA score. 
This argues against the EPh1 deletion having destabilized the DARPin and the 
ribosome display selected mutations compensating for it. Instead, the data are 
consistent with the dimerization and multimerization of EPh1 be entirely due to 
a fortuitous self-complementarity of the surface of native DARPin molecules, and 
the evolution process having removed some interacting residues and thus 
leading to monomers, at the same time leading to picomolar affinity to the 
target EpCAM 
The ability of the six DARPins to interact with EpCAM on the cell surface 
was determined by flow cytometry. All DARPins bound to EpCAM-positive cells 
but not to EpCAM-negative control cells. The unselected DARPin E3_5 did not 
interact with any of the tested cell lines (Figure 5C). 
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We further analyzed if the two families bind to different EpCAM epitopes 
by flow cytometry. To this end, binding of Ec4_sfGFP in the presence of an excess 
of Ac2, and binding of Ac2_sfGFP in the presence of an excess of Ec4 to MCF-7 
cells was analyzed. Since no mutual competition was observed, we conclude that 
the two families recognize non-overlapping epitopes. Additionally, as expected 
Ec4, the Eph1 derived binder, competed for binding with the EpCAM antibody, 
MOC31, while Ac2 did not (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 5. A) Competition ELISA binding assay. Biotinylated EpCAM (10 
nM) was immobilized on streptavidin-coated plates. EpCAM-binders (10 nM) 
were allowed to bind for 10 min. For competition, binders were preincubated 
with a 10-fold excess of non-biotinylated EpCAM. Detection was done with 
mouse anti-RGS(His)4 as primary and alkaline phosphatase-coupled goat anti-
mouse IgG as secondary antibody. B) Analytical gel filtration. 15µM DARPin (50 
µL) were analyzed on an Ettan™ liquid chromatography system using a 
Superdex™ 200 column (both GE Healthcare). C) Analytical flow cytometry. 
EpCAM-positive SW2 cells were incubated at 4°C with the EpCAM-specific 
DARPins for 1h. Detection with mouse anti-RGS(His)4 as primary and Alexa Fluor 
488 coupled goat anti-mouse IgG as secondary antibody. Blue: autofluorescence 
of SW2 cells, red: unselected library member (negative control), rest: EpCAM-
specific DARPins. Specificity of depicted DARPins was confirmed with EpCAM-
negative cells RL. Blue: autofluorescence of RL cells, rest: EpCAM-specific 
DARPins. 
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Affinity determination of Ec4 
 
We determined the dissociation constant (KD) of Ec4, by surface plasmon 
resonance (SPR) with purified bEpEx as 920 ± 80 pM.  
We also wished top determine the affinity for EpCAM on cells, and 
therefore used flow cytometry of Ec4_sfGFP on MCF-7 cells, using the 
determination of association and dissociation rates on cells (39) under conditions 
where internalization was minimized. The calculated functional affinity on cells 
was 7.9 ± 0.5 nM (Figure 6).  
The difference in affinities to SPR measurements was entirely due to an 
almost 10-fold slower kon, whereas the dissociation rate was identical in both 
experimental setups. The slower association is not caused by the bigger size of 
the DARPin-GFP fusion, as the same binder coupled to Alexa Fluor 488 bound to 
cells at a similar rate. Therefore, we suggest that this lower on-rate is due to a 
limited access of the cognate epitope on the cell surface. 
 
Figure 6. Association and dissociation of Ec4-sfGFP from EpCAM-positive MCF-7 
cells. For dissociation, cells were incubated with 100 nM Ec4_sfGFP for 1h at 4°C, 
washed, resuspended in 1 µM Ec4 (t=0) to prevent rebinding. For association, 
cells were resuspended in 2.5, 7.5 and 22.5 nM Ec4-sfGFP (t=0). Mean 
Fluorescence intensities measured on a FACScanto II analytical flow cytometer 
(BD Biosciences) at different time points were used to calculate ka, kd andKD.
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Discussion 
 
The aim of this study was the generation of specific binders from a 
DARPin library against the tumor-associated antigen EpCAM. EpCAM is widely 
expressed on solid tumors and upon ligand binding, it is efficiently internalized 
by receptor-mediated endocytosis. Thus, it perfectly matches the need for 
intracellular delivery of anticancer agents acting on intracellular targets such as 
DNA-damaging agents, toxins, antisense oligonucleotides and siRNA (14, 16-17, 
37). 
The extracellular domain of EpCAM was expressed in HEK293T cells and 
used as target protein for our DARPin selections, as it is glycosylated in several 
positions (40). We employed two different selection techniques, SRP phage 
display and ribosome display with the purified protein. Both selection techniques 
were found to be well-suited for the in vitro selection of binders from synthetic 
DARPin libraries.  
After the initial selection by phage display on immobilized target we 
found one dominant binder, named EPh1, having a characteristic two-amino-acid 
deletion between the N-terminal capping repeat and the first internal repeat. 
This deletion was not observed in other selections performed with the same 
library. It appears to favor binding to a particular epitope, since when the two 
amino acids were reinserted, binding affinity was significantly reduced. Selection 
of only one dominant binder or a low diversity of binders selected on certain 
target proteins is a common phenomenon often observed with phage display 
(29). In this case, the deletion — which most likely happened in the original 
assembly of the library from synthetic oligonucleotides — is a very rare event, 
leading in this case to a very valuable clone, for which there was no alternative. 
This particular clone appeared to show fortuitous self-complementarity, which 
could be completely removed during a further maturation by ribosome display, 
showing the great powers of evolutionary optimization. We assume that no 
equivalent binder was found be selecting directly from the ribosome library since 
no similar 2-amino-acid deletion molecule may have been present in the 
ribosome display libraries. 
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To overcome this limitation, we employed epitope masking to recover 
binders recognizing other epitopes (32). The five new binders so obtained 
specifically recognized EpCAM in ELISA failed to bind to EpCAM expressed on the 
cellular surface, and only EPh1 was capable of binding to EpCAM expressed on 
different tumor cells. It is possible that during the selection procedure, soluble 
EpCAM may have exposed additional epitopes which are normally hidden when 
EpCAM is anchored in the cell membrane. Additionally, blocking the preferred 
epitope may make even closely adjacent ones inaccessible, thereby directing 
binding to epitopes too close to the cell membrane, or those that are 
inaccessible by oligomerization of EpCAM (35), or EpCAM interaction with other 
molecules on the cell surface. EpCAM was shown to interact with the tight 
junction protein claudin-7 followed by recruitment into tetraspanin-enriched 
membrane microdomains where it is complexes with tetraspanin and CD44v6 
(9). 
Ribosome display selection using an N2C and an N3C DARPin library (19) 
resulted in seven new binders that belong to three families. None of these 
families featured the same randomized positions as EPh1, nor its 2-amino-acid 
deletion. All binders selected by ribosome display were capable of binding to 
EpCAM in its native conformation on cells. One of these DARPins, C9, was tested 
to explore its potential use for tumor-targeting (37). However, its affinity was in 
the mid-nanomolar range and therefore, it was also converted to different 
dimeric forms, and fused to protamine, a highly positively charged peptide that 
can complex small interfering RNA. These fusion proteins efficiently delivered 
siRNA complementary to bcl-2, a potent inhibitor of apoptosis implicated in 
cancer drug resistance and successfully down-regulated bcl-2 expression in an 
EpCAM-specific manner, facilitating cell-specific apoptosis (37). 
We then used affinity maturation to improve all previously selected 
binders by combining error-prone PCR with stringent selection by ribosome 
display (26, 30). Of the finally chosen 6 binders, two were derived from the 
ribosome display pool and four of the binders were derived from Eph1 selected 
by SRP phage display. Members of this group maintained not only the same 
randomized positions but also the characteristic two-amino-acid deletion found 
in EPh1 and had four to six different framework mutations. These framework 
mutations eliminated any self-association tendency that the precursor EPh1 had, 
and these proteins were pure monomers. An analysis by ROSETTA gave no 
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indication that EPh1 had any problematic amino acids that were "corrected", and 
it thus directed evolution appears to have eliminated surface features that have 
allowed self-complementarity. 
One of the evolved binders Ec4 was characterized in more detail. Its 
binding on cells showed a slower on-rate than measured by SRP, leading to low 
nanomolar KD on cells, while it is subnanomolar in SPR measurements. Ec4 
similarly to their parental binder EPh1, is internalized into cells upon binding to 
EpCAM, which is a mandatory prerequisite for the delivery of therapeutic 
molecules acting on intracellular targets. 
Since we determinated that Ec4 recognize a different epitope on EpCAM 
than Ac2 (another evolved binder), we were able to further enhance the 
functional affinity of the binders on cells by generating dimers and tetramers of 
the two DARPins by fusion to a self-associating peptide. Preliminary data show 
that this multimerization enhances the binding activity due to an up to 100-fold 
decrease in the dissociation rate (N Stefan, unpublished) 
In summary, we found merit in using both phage display and ribosome 
display to select binders for a demanding highly glycosylated target which may 
present only few accessible epitopes. By combining both selection methods and 
subsequent stringent directed evolution we generated high affinity binders to 
non-overlapping epitopes of EpCAM. These DARPins expressed at high yield and 
could be easily purified. Since they can be linked in many new formats and are 
efficiently internalized, they may provide the basis for a new generation of 
protein therapeutics, which are superior to antibodies in terms of stability, 
production, biophysical properties and freedom for rational engineering and 
optimization. 
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Abstract 
 
Purpose: Designed Ankyrin Repeat Proteins (DARPins) hold great promise 
as a new class of binding molecules to overcome the limitations of antibodies for 
biomedical applications. Here, we assessed the potential of an EpCAM-specific 
DARPin (Ec4) for tumor targeting in form of a fusion toxin with Pseudomonas 
exotoxin A. 
Experimental design: DARPin Ec4 was genetically fused to a truncated 
form of exotoxin A (ETA") and expressed in E.coli. The cytotoxicity of Ec4-ETA" 
was measured against tumor cell lines of various histotypes in vitro. Tumor 
localization and anti-tumor activity were determined in athymic mice bearing 
EpCAM-positive tumor xenografts.  
Results: Ec4-ETA" expressed very well in soluble form in the cytoplasm of 
E. coli and yielded up to 40 mg after purification per liter culture. The protein 
was shown to be monomeric and the disulfides of ETA" formed spontaneously. 
Ec4-ETA" bound to EpCAM with picomolar affinity, similar to free Ec4. 
Furthermore, it was highly cytotoxic against various EpCAM-positive tumor cell 
lines in vitro with IC50 values less than 0.005 pM. This effect was competed by 
free Ec4, but not unspecific DARPins. Upon systemic administration in athymic 
mice, Ec4-ETA" efficiently localized to EpCAM-positive tumors to achieve 
maximum accumulation 48-72 h after injection, whereas an irrelevant control 
fusion toxin did not. Tumor targeting with Ec4-ETA" resulted in a strong anti-
tumor response including complete regressions in some animals. 
Conclusions: Our data demonstrate for the first time the potential of 
DARPins for the generation of protein therapeutics for tumor targeting, and that 
Ec4-ETA" deserves attention for clinical development. 
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Introduction 
 
 
The concept of tumor-targeted therapy is based on the use of conjugates 
consisting of ligands binding to tumor-associated antigens or growth factor 
receptors which deliver cytotoxic agents selectively to tumors, while sparing 
normal tissues from destruction (1). These agents include radioisotopes, small 
organic compounds, antisense oligonucleotides and protein toxins. All of them 
exert different modes of action, compared to standard chemotherapy, and thus 
might be particularly useful to combat drug-resistant cancer. Nonetheless, it 
remains to be shown in every single case whether a tumor-specific localization 
actually occurs and what profile of anti-tumor action compared to side effects is 
seen. 
Immunotoxins are a class of conjugates in which antibodies or antibody 
fragments are chemically linked to protein toxins, whereas in the more advanced 
constructs targeting ligand and toxin are genetically fused (2). The most popular 
toxins used for this purpose are diphtheria toxin and Pseudomonas aeruginosa 
exotoxin A (ETA) (3), which both act by irreversibly inhibiting protein synthesis in 
cells. In ETA-based fusion toxins a truncated variant lacking the cell binding 
domain and carrying a C-terminal KDEL peptide (denoted here ETA") is 
commonly used (4). Currently, several of these fusion toxins are in clinical trials 
for the treatment of lymphomas, leukemias (5-6), mesothelioma and cancers of 
the ovary, pancreas and bladder (7-8). 
On solid tumors, well investigated targets for antibody-based therapies 
are members of the epidermal growth factor receptor family such as EGFR itself 
and ErbB2, and certain tumor-associated carbohydrates (2, 9). Recently, the 
epithelial cell adhesion molecule (EpCAM) has also emerged as a promising 
structure for targeted therapy of solid tumors. One reason is that its efficient 
internalization promotes access of surface bound effector molecules to 
intracellular targets (10-13). EpCAM is a homophilic cell adhesion molecule of 39 
to 42 kDa, consisting of an extracellular domain with an epidermal growth factor-
like and a human thyroglobulin-like domain, and a short cytoplasmic domain. Its 
processing by regulated intramembrane proteolysis releases a cytoplasmic tail 
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which activates the wnt signaling pathway and induces transcription of c-myc 
and cyclins (14-15). How this mechanism contributes to tumor progression in 
vivo is unclear. EpCAM is expressed at low levels on basolateral cell surfaces of 
some normal epithelia where it is, however, poorly accessible to circulating anti-
EpCAM antibodies (16). On the other hand, high levels of homogenously 
distributed EpCAM are detectable on cells of epithelial tumors (14, 17), and its 
overexpression represents an independent prognostic marker for reduced 
survival in patients with breast and ovarian cancer (18-19). Recently, EpCAM was 
also identified as a marker of cancer-initiating cells in colon (20), breast (21) and 
pancreatic cancers (22), providing the opportunity to target stem-like cells, which 
usually respond poorly to standard therapy. The favorable properties of EpCAM 
for cancer therapy are currently exploited in phase II clinical trials with a scFv-
ETA" immunotoxin (8, 10-13) which we developed previously. 
Nowadays, the tumor-targeting moiety for the delivery of cytotoxic 
agents including protein toxins is usually derived from antibodies or antibody 
fragments, which, however, have practical limitations due to their poor 
expression yield and aggregation tendencies, at least for some constructs (23-
24). Since for fusion toxins no other feature of the antibody is required than 
antigen binding, a solution might come with the use of alternative non-IgG 
binding scaffolds as targeting moieties. These can be engineered for improved 
specificity, affinity, and stability to increase the production yield. One such 
protein class are Designed Ankyrin Repeat Proteins (DARPins) (25-27). The 
ankyrin repeat motif consists of 33 amino acids forming a loop, a β-turn and two 
antiparallel α-helices connected by a tight turn. Their high stability and favorable 
biophysical properties provide proteins which tolerate engineering procedures 
usually not applicable to antibodies. Moreover, they contain no cysteine which 
can instead be introduced for site-specific modifications. Thus, DARPins fulfill the 
requirement of almost ideal candidates for many biomedical applications 
including tumor targeting. Using combinatorial libraries of DARPins along with 
selection by ribosome or phage display, we recently generated several binders 
specific for EpCAM, and demonstrated their potential for efficient delivery of 
therapeutic siRNA into tumor cells (Martin Killias et al., in preparation,(13). 
Here we describe for the first time the use of a high affinity DARPin (Ec4) 
specific for EpCAM to generate a fusion toxin with ETA". Ec4-ETA" expressed very 
well in E. coli, was easily purified to high yields, and proved to be specifically 
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cytotoxic against various EpCAM-positive tumor cell types in vitro. In vivo, 
fluorescence imaging and therapy studies in athymic mice demonstrated its 
ability to efficiently localize to subcutaneously growing tumors upon intravenous 
administration, and induce strong anti-tumor effects including complete 
regressions. 
 
 
 
Translational Relevance 
 
Antibodies or antibody fragments are widely used as targeting moiety for 
the delivery of cytotoxic drugs to tumors. However, many of these constructs 
have limitations due to their poor expression and aggregation tendency. To 
overcome these limitations, we used for the first time Designed Ankyrin Repeat 
Proteins (DARPins) as non-IgG scaffolds with favorable biophysical properties and 
much higher expression yield in E. coli and systematically tested its potential for 
tumor-targeted delivery of a highly potent biotoxin in preclinical studies. The 
fusion toxin Ec4-ETA" recognizing the carcinoma-associated antigen EpCAM was 
potently cytotoxic against carcinoma cell lines of various histotypes in vitro. In 
athymic mice targeting of human carcinoma xenografts with Ec4-ETA" resulted in 
a strong anti-tumor response including complete regressions. This demonstrates 
that DARPins are well suited for tumor targeting and that the fusion toxin Ec4-
ETA" holds promise for clinical development. 
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Material and Methods 
Tumor cells 
The squamous cell carcinoma cell line of the tongue CAL27 and the 
colorectal carcinoma cell line HT29 were obtained from DSMZ (Deutsche 
Sammlung von Mikroorganismen and Zellkulturen, Braunschweig, Germany). The 
breast carcinoma cell line MCF7 and the non-Hodgkin's lymphoma cell line RL 
were obtained from ATCC (American Type Culture Collection). The small cell lung 
carcinoma cell line SW2 was maintained in our laboratory. All cells were cultured 
in Dulbecco's modified medium (DMEM) (Sigma, Buchs, Switzerland), 
supplemented with 10% fetal calf serum (Amimed, Bioconcept, Allschwil, 
Switzerland), 100 units/ml of penicillin and 100 µg/ml of streptomycin (Sigma). 
Cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. All 
cells were tested negative for mycoplasma using MycoAlert (Lonza, Basel, 
Switzerland). 
 
Construction, expression and purification of DARPin-ETA" fusion toxins 
The EpCAM-specific high affinity DARPin Ec4 was selected from a DARPin 
library as described (Martin Killias et al., in preparation), the control DARPins off7 
(targeting the maltose binding protein) and E3_5 (an unselected member of the 
N3C library) have been described elsewhere (26-27). The sequences encoding 
the DARPins were inserted via BamHI and HindIII upstream into a expression 
vector derived from pQE30 , containing a 12 amino acid linker (GSG4)2 and the 40 
kDa truncated form of ETA252-608KDEL (ETA") which was cloned as described (10, 
28). ETA comprises residues Glu252-Pro608 (numbering of the mature protein), 
fused to a C-terminal his tag followed by KDEL (denoted ETA252-608KDEL or ETA"). 
For purification and detection the construct in addition contains an 
MRGS-His6 tag at the N terminus. The DARPin-ETA" fusion proteins were 
expressed in soluble form in E. coli  BL21(DE3) strain (Stratagene, La Jolla, USA). 
Cultures were harvested 4 h after induction with 1 mM IPTG. For purification the 
bacteria were resuspended in TBS400 (50 mM Tris, 400 mM NaCl, pH 7.4 at 4°C) 
with 20 mM imidazole and lysed with a TS 1.1 kW cell disruptor (Constant 
Systems Ltd., Northants United Kingdom). Upon centrifugation (48000 g, 30 min 
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at 4°C) and filtration (pore size 0.22 µm), the fusion toxins present in the clear 
supernatant were purified by immobilized metal ion affinity chromatography 
(IMAC) using Ni-NTA superflow (Qiagen, Hilden, Germany). 
 
Endotoxin removal 
For in vivo application, the DARPin-ETA" fusion toxins were further 
purified to eliminate endotoxin. To this end, an additional washing step with 150 
column volumes PBS containing 20 mM imidazole and 0.1% Triton-X-114 was 
performed during Ni-NTA purification, followed by size exclusion 
chromatography using a Superdex 200 10/300 GL column (GE Healthcare, Zürich, 
Switzerland). Monomeric fractions were further depleted of residual endotoxin 
by passage over an EndoTrap Red column (Hyglos, Regensburg, Germany), and 
the final endotoxin content was determined using a commercially available 
Limulus amebocyte lysate (LAL) endochrome kit (Charles River, Sulzfeld, 
Germany). 
 
Measurement of EpCAM-binding affinity 
The EpCAM-binding affinity of Ec4-ETA” was measured by surface 
plasmon resonance using a Biacore 3000 (GE Healthcare) instrument. A 
streptavidin (SA) chip was coated with 120 resonance units (RU) of biotinylated 
extracellular domain of EpCAM (residues 1 to 242 of the mature protein). 
Measurements were performed by serial injection of different concentrations of 
Ec4-ETA" ranging from 10 to 160 nM at a buffer flow of 30 µl/min in HBST (20 
mM Hepes, pH 7.4, 150 mM NaCl, 3mM EDTA, 0.005% Tween-20). Data 
evaluation was performed using the BIAEVAL software (GE Healthcare) and 
Scrubber 2 (BioLogic Software, Campbell, Australia). 
 
Disulfide assays 
The formation of the two disulfide bonds in Ec4-ETA" after purification of 
protein expressed in the cytoplasm was quantified according to (29). Briefly, 1.25 
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nmol of fusion protein was treated with 4,4′-dithiodipyridine (4-DPS) and 
compared to a sample reduced with sodium borohydride, quantified by HPLC 
and evaluated according to a standard curve made with known amounts of 
cysteine. 
 
Cytotoxicity assays 
The specific cytotoxic activities of the DARPin-ETA” fusion toxins were 
assessed by measuring cell viability in standard colorimetric XTT assays (XTT = 
(2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tretrazolium-5-carboxanilide) 
sodium salt) (Roche, Basel, Switzerland). Briefly, EpCAM-positive or negative 
tumor cells were seeded at 5000 cells per well in a 96-well plate and incubated 
overnight at 37°C under standard cell culture conditions as described above. The 
fusion proteins were added to the cells at the indicated concentrations to a final 
volume of 100 µl. After 72 h, 50 µl of XTT reagent was added as specified by the 
manufacturer's protocol and cells were further incubated for 2 h. The 
absorbance at 450 nm was measured with a HTS 7000 plus microplate reader 
(Perkin Elmer, Wellesley, USA) and cell viability was calculated after subtraction 
of blanks (wells without cells) as the percentage of living cells in treated wells 
relative to untreated cells (cells without DARPin-ETA” toxin). 
 For competition analysis of specificity, cells were first preincubated for 10 
min with unconjugated DARPins at the concentrations indicated before Ec4-ETA" 
was added and viability was determined as described above. 
 
Fluorescence labeling of DARPin-ETA" fusion proteins with Cy5.5 
Ec4-ETA" and off7-ETA" were incubated with a 3-fold molar excess of 
Cy5.5 NHS ester (GE Healthcare) pH 7.4 for 1.5 h at room temperature. The 
samples were passed over a PD-10 column (GE Healthcare) to remove unreacted 
dye and exchange the buffer to 100 nM sodium-bicarbonate with 20 nM NaCl at 
pH 8. At this relatively low pH the N-terminal amino group is favored over lysine 
residues. Monolabeled fusion proteins were separated from unlabeled and 
multiple labeled proteins by anion exchange chromatography on a MonoQ 
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column (GE Healthcare) in 100 nM sodium-bicarbonate and 1 M NaCl at pH 8 for 
isocratic elution. 
 
Animals and tumor xenografts 
For in vivo experiments, 8-10 weeks old female athymic mice (NMRI 
nu/nu, Harlan Laboratories, B.V., The Netherlands or CD1, Charles River, Sulzfeld, 
Germany) were used. Mice were housed and maintained under specific 
pathogen free conditions according to the guidelines of the veterinary offices of 
the Kanton Zürich and Bern. Tumors were raised by subcutaneous (s.c.) injection 
into the lateral flank of HT29 cells (107 cells in 100 µl PBS). 
 
In vivo fluorescence imaging 
Ten days after s.c. tumor cell injection, mice were intravenously (i.v) 
injected with 30 µg of Ec4-ETA" or off7-ETA" conjugated with the fluorescent dye 
Cy5.5 (n=3 for each group). In vivo imaging was performed 6, 24, 48, 72, and 96 h 
after injection. During imaging mice were anaesthetized by intraperitoneal (i.p.) 
injection of body-weight adapted doses of 10% ketamine and 2% xylazin. In 
addition, 48 h after i.v. injection one mouse of each group was euthanized and 
fluorescent images of dissected organs were obtained. Images were acquired 
using the NightOwl II NC100, Type LB 893, 2006“ imaging system (Berthold 
Technologies, Bad Wildbad, Germany) with an exposure time of 60 s. For 
colocalization of the fluorescent image on the animal body, gray scale and 
pseudocolor images were merged. Quantification of signal intensity in all animals 
was performed with WinLight32 Software. 
 
Anti-tumor activity in vivo 
Mice bearing established tumors of 50 to 100 mm3 in size were i.v. 
injected on days 1, 3 and 5 with either 30 µg or 20 µg Ec4-ETA" or with 30 µg 
off7-ETA" in 100 µl PBS. Mice treated with PBS at the same time points were 
used as control. Treatment with the Ec4-ETA" lower dose (20 µg) was repeated 
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again on days 9, 13 and 15. Animals were monitored for tumor growth by caliper 
measurement of the shortest diameter and the longest perpendicular diameter. 
Tumor volume was calculated according to the formula (short diameter)2 x (long 
diameter) x 0.4. Mice were euthanized when tumors reached a volume of 1500 
mm3 or when tumors showed skin ulcerations. 
 
In vivo toxicity determination 
During treatment with the fusion toxins animals were controlled daily for 
weight loss or other signs of toxicity and discomfort (apathy, ungroomed 
appearance, dehydration, etc). Liver toxicity was assessed post mortem by 
measuring alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
activity in plasma samples. Blood samples from 2 mice treated with PBS and 3 
mice treated with 30 µg Ec4-ETA" three times every second day were collected 
24 h after the final injection. Upon plasma separation, ALT and AST activities 
were measured photometrically. 
 
Statistical analysis 
All data represent the mean ± SD. Statistical analyses of in vivo tumor 
growth were performed using the Kruskal-Wallis test. P < 0.05 was considered 
statistically significant. 
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Results 
 
Expression and purification of DARPin-ETA" fusion proteins 
 
The EpCAM-specific high-affinity DARPin Ec4 (Martin Killias et al., in 
preparation) and the control DARPins off7 (26) and E3_5 (27) were fused via a 
(GSG4)2 linker to a truncated form of Pseudomonas exotoxin A (residues Glu252-
Pro608, numbering of the mature protein), containing a C-terminal KDEL 
(denoted ETA252-608KDEL or ETA") to increase cytotoxicity in mammalian cells 
(30). For purification and detection, the constructs further contained a His6 tag at 
the C-terminus in front of the KDEL sequence and a RGSHis6 tag at the N-
terminus. 
 All DARPin-ETA" fusion proteins were expressed in soluble form in E. coli 
at 37°C. The protein yield was up to 40 mg/liter of bacterial culture. Purification 
was achieved using immobilized metal ion affinity chromatography (IMAC), 
which for in vivo experiments was followed by extensive Triton X-114 washing, 
size exclusion chromatography and an EndoTrap column to remove endotoxin. 
The fusion toxins showed a band at the predicted molecular weight of around 59 
kDa when analyzed on SDS-PAGE (Figure 1A), and size exclusion chromatography 
revealed a mainly monomeric fraction (Figure 1B). Figure 1C shows a computer 
model of Ec4-ETA". ETA" contains two disulfide bonds, and although the fusion 
toxins were expressed in the bacterial cytoplasm, quantitative disulfide assays 
(see Materials and Methods) revealed that > 90% of the protein had both 
disulfide bonds formed after purification, most probably by spontaneous air 
oxidation (data not shown). We conclude from these findings that DARPins are 
well suited for the easy and cost-effective production of fusion toxins for tumor 
targeting. 
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Figure 1. Biochemical characterization of the DARPin-ETA” fusion 
protein toxins.. Biochemical characterization of the DARPin-ETA” fusion toxins. A 
For SDS-PAGE analysis, fractions were loaded onto a 10% polyacrylamide gel and 
proteins were detected by staining with Coomassie brilliant blue: lane M: 
molecular weight marker (kDa), lane 1: uninduced bacterial cell lysate, lane 2: 
cell lysate 4 h after induction, lane 3: purified Ec4-ETA”, lane 4: purified off7-
ETA”, and lane 5: purified E3_5-ETA”. B Size exclusion chromatography of 
DARPin-ETA” fusion toxins analyzed on a Superdex 200 10/300 GL column. C 
Model of the DARPin-toxin construct was built based on the X-ray structures of a 
consensus DARPin (PDB entry 2QYJ) and Pseudomonas aeruginosa exotoxin A 
(ETA) (1IKQ) using InsightII (Accelrys) and the ROSETTA suite programs. The 
DARPin targeting moiety is shown in cyan, ETA domain Ib in purple, domain II in 
orange and domain III in red. The flexible N-terminal RGS-His6-tag, the C-terminal 
His6 tag and KDEL ER-retention signal (blue) as well as the linker connecting the 
DARPin to the toxin (green) were modeled in to visualize their sizes relative to 
those of the protein domains. The figure was generated using the program 
PyMol (DeLano Scientific LLC, Palo Alto, CA, USA). 
  
95 
EpCAM-binding affinity of Ec4-ETA" 
 
To investigate whether the fusion to ETA” impaired the binding activity of 
DARPin Ec4 to EpCAM, the dissociation constant (KD) of the fusion protein Ec4-
ETA” was measured by surface plasmon resonance (SPR) ( Figure 2). The KD was 
calculated as 920 ± 60 pM, which was essentially the same as measured for the 
Ec4 DARPin (Martin Killias et al., in preparation). 
 
Figure 2. Determination of the EpCAM-binding affinity of Ec4-ETA” by SPR 
measurement. Enzymatically biotinylated EpCAM was immobilized on a 
streptavidin chip and increasing concentrations of Ec4-ETA” (5 nM, 10 nM, 20 
nM, 40 nM, 80 nM, 160 nM) were assayed.Association and dissociation phases 
were recorded. From a measured association rate constant of 8.7 +/- 0.5 104 M-
1s-1 and a dissociation rate constant of 8.0 +/- 0.08 10-5 s-1 a KD of 920 +/- 60 pM 
was calculated. 
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Cytotoxicity of Ec4-ETA" against various tumor cell lines in 
vitro 
 
The cytotoxic effect of Ec4-ETA” and the control fusion proteins off7-ETA” 
and E3_5-ETA” on various EpCAM-positive tumor cell lines and EpCAM-negative 
control cells was determined in colorimetric XTT cell viability assays upon a 72 h 
incubation. As shown in Fig. 3A, Ec4-ETA” was potently cytotoxic against all 
EpCAM-positive cell lines tested, MCF7, SW2, CAL27 and HT29. The IC50 values 
(concentration at which cell viability was reduced by 50%) ranged from less than 
0.005 pM to 0.7 pM. In contrast, the effect on EpCAM-negative RL cells was more 
than 100'000-fold lower (IC50 > 10 nM). Similarly, the unspecific fusion proteins 
off7-ETA" and E3_5-ETA" showed cytotoxic effects only at much higher 
concentrations (IC50 > 1 nM) when tested on EpCAM-positive HT29 cells (Figure 
3B). 
Furthermore, the cytotoxicity of Ec4-ETA" was markedly decreased when 
cells were preincubated with an excess of unfused DARPin Ec4 (Figure 3C). This 
decrease was specific for EpCAM blocking as preincubation with the non-specific 
DARPins off7 and E3_5 did not diminish Ec4-ETA" cytotoxicity. Moreover, the use 
of the DARPins alone did not affect cell viability (data not shown). Taken 
together, these data show that the cytotoxicity is mediated by EpCAM-specific 
uptake and background cytotoxicity by unspecific uptake of the DARPin-ETA" 
fusion proteins was in general very low. 
 
 
 
  
97 
 
Figure 3. In vitro cytotoxicity of Ec4-ETA” and the control fusion toxins off7-ETA” 
and E3_5-ETA” tested on various tumor cell lines. A The EpCAM-positive cell lines 
MCF7, SW2, CAL27, HT29, and the EpCAM-negative cell line RL were incubated 
for 72 h with different concentrations of Ec4-ETA” before cell viability was 
determined in colorimetric XTT assays. B. HT29 cells were incubated with the 
unspecific fusion proteins E3_5-ETA” or off7-ETA” for 72 h in XTT assays, and 
viability was compared to cells treated with Ec4-ETA” 
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Figure 3. C In competition assays, EpCAM-positive HT29 cells were incubated 
with DARPin Ec4, E3_5 and off7 (500 nM) 10 min before Ec4-ETA” was added and 
cell viability determined as described before. All determinations were done in 
triplicates, data represent the mean ± SD 
 
 
Tumor localization of Ec4-ETA" 
To demonstrate that Ec4-ETA" efficiently localizes to tumors upon 
systemic administration and that this effect is EpCAM-dependent, in vivo 
fluorescence imaging was performed in athymic mice bearing s.c. HT29 tumor 
xenografts. Ec4-ETA" and off7-ETA" control were N-terminally labeled with the 
fluorescent dye Cy5.5 (emission maximum 680 nm). After the coupling reaction, 
the labeled proteins were purified by anion exchange chromatography to 
eliminate unlabeled protein, free dye and other labeled protein species. Mice 
were injected i.v. with 30 µg Ec4-ETA"_Cy5.5 or off7-ETA"_Cy5.5, and images 
were taken after 6, 24, 48, 72 and 96 h using the NightOWL II LB891 imaging 
system. As shown in Fig. 4A, 6 h after injection both fusion proteins localized to 
the lower abdomen which could be identified as mainly kidney and partially liver 
accumulation. Ec4-ETA" efficiently localized to tumors 24 h after injection, and 
accumulation peaked between 48 h and 72 h before it declined to background 
values after 96 h. In contrast, only very low background fluorescence was 
detectable in the tumors upon injection of the non-targeted fusion protein off7-
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ETA". Furthermore, we performed ex vivo analysis of biodistribution in isolated 
organs and tumors 48 h after injection of the fluorescent-labeled probe using a 
fiber optic device. As shown in Fig. 4B, similar to whole animal imaging high 
fluorescence activity in the tumor was detected only in mice injected with Ec4-
ETA" but not off-7-ETA". Both fusion proteins, however, showed localization in 
the liver and at low levels in the intestine, which likely reflects their metabolic 
degradation.  
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Figure 4. Tumor localization and organ distribution of Cy5.5-labeled Ec4-ETA" 
and the off7-ETA" control fusion toxin detected by in vivo fluorescence imaging. 
Mice bearing s.c. HT29 tumor xenografts were intravenously (i.v) injected with 30 
µg of Ec4-ETA” or off7-ETA" conjugated with the fluorescent dye Cy5 (n=3 for 
each group). A. In vivo images were acquired 6, 24, 48, 72, and 96 h after 
injection using the NightOWL II LB891 imaging system with an exposure time of 
60 s. For colocalization of the fluorescent image on the animal body, gray scale 
and pseudocolor images were merged. ND: not determined. B Ex vivo analysis of 
fluorescence intensities from isolated tumors and organs 48 h after injection of 
Cy5.5-labeled Ec4-ETA" or off7-ETA" using a fiber optic device. Samples of one 
representative mouse of each group are shown. 
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Anti-tumor effect of Ec4-ETA" 
To investigate how the favorable tumor localization of Ec4-ETA" 
translates into therapeutic efficacy, its anti-tumor effect was also evaluated in 
athymic mice bearing established s.c. HT29 tumor xenografts. In one group, mice 
received 3 doses of 30 µg Ec4-ETA" (Ec4-ETA" 30/3) on days 1, 3 and 5. In a 
second group, 6 doses of 20 µg Ec4-ETA" (Ec4-ETA" 20/6) were administered on 
days 1, 3, 5, 9, 13 and 15. Control mice received PBS or 3 doses of 30 µg off7-
ETA" (off7-ETA" 30/3) on days 1, 3 and 5. 
As shown in Figure 5A, tumors of control mice treated with PBS grew 
rapidly until the end of the observation period. In contrast, in all mice treated 
with Ec4-ETA" tumor growth was strongly inhibited. Tumors of mice treated with 
the Ec4-ETA" 30/3 schedule almost completely disappeared after the last 
injection, but started to regrow when treatment was discontinued. Nonetheless, 
in this group 2 of 11 mice (18%) showed complete regression, defined as non-
detectable tumor or no tumor regrowth for more than 45 d. The anti-tumor 
effect of the Ec4-ETA" 20/6 schedule was even more pronounced, resulting in 2 
of 5 mice (40%) with complete regressions. Treatment with the control fusion 
protein off7-ETA" 30/3 had no effect on tumor growth compared to mice treated 
with PBS. 
To better discriminate between the response rates in the various groups, 
Kaplan-Meier curves were plotted with an end point defined as a tumor size > 
100 mm3. As shown in Figure 5C, all control mice treated with PBS or off7-ETA" 
developed tumors > 100 mm3 already 9 d after the start of treatment. At this 
time point, all mice in the Ec4-ETA"-treated group had tumors clearly below this 
size. On day 31, 18% of mice treated with Ec4-ETA" 30/3 and 60% of mice treated 
with Ec4-ETA" 20/6 still showed tumors < 100 mm3, indicating that treatment 
with the Ec4-ETA" 20/6 schedule was more effective in tumor control than with 
Ec4-ETA" 30/3. At the end of the experiment (day 31), the average size of tumors 
was significantly reduced from 1005 +/- 275 mm3 (PBS group) to 189 +/- 123 
mm3 in the Ec4-ETA" 30/3 treated group (P < 0.05) and to 95 +/- 79 mm3 in the 
Ec4-ETA" 20/6 treated group (P < 0.05). This reflects a reduction in tumor volume 
of 81% and 91%, respectively. The favorable effect of the Ec4-ETA" 20/6 
treatment is also reflected in the 40% complete regressions (see above). No 
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difference in tumor size was found in mice treated with off7-ETA" 30/3 
compared to PBS. 
 
 
 
Figure 5 Anti-tumor effect of Ec4-ETA” in athymic mice. A. Mice bearing s.c. 
growing HT29 tumor xenografts of 50 to 100 mm3 in size received tail-vein 
injections of either 3 x 30 µg Ec4-ETA”, 3 x 30 µg off7-ETA” control, 6 x 20 µg Ec4-
ETA” or PBS as vehicle control. Tumor growth was monitored by caliper 
measurement during the course of 31 days. Data represent the mean tumor 
volume ± SD of 5 to 11 mice per group. 
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Figure 5 B. Kaplan-Meier survival curves with an endpoint defined as tumor 
volume of 100 mm3. The curves show the percentage of treated mice in each 
group in which tumors did not exceeded 100 mm3 in size at the various time 
points after the start of treatment. C. Pictures of representative tumors isolated 
from mice of the different treatment groups 
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Toxicity of Ec4-ETA" 
To determine treatment-related unspecific toxicity upon Ec4-ETA" and 
off7-ETA" administration, mice were monitored for weight loss, dehydration and 
signs of distress (apathy, hyperalgesia and ungroomed appearance) throughout 
the course of the study. Figure 6 shows that all treatments were well-tolerated 
and after reversible marginal weight loss after the third injection of Ec4-ETA” 
30/3 no further signs of toxicity were observed. Furthermore, to assess liver 
toxicity as a frequent dose-limiting side effect of ETA fusion toxin therapy in 
patients, blood from 2 PBS-treated mice and 4 mice receiving 3 doses of 30 µg 
Ec4-ETA" was collected and analyzed for activity of the liver transaminases 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT). As shown 
in Table 1, liver toxicity could be excluded for this treatment schedule as there 
was no elevation of ALT and AST activity in the plasma of Ec4-ETA"-treated 
compared to PBS-treated mice. 
 
Figure 6. Average weight of mice upon treatment with different dose schedules of Ec4-
ETA", or off-7-ETA" or with PBS control. Animals were weighed three times per week 
during the whole experiment to monitor treatment-related toxicity.  
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Table 1. Liver transaminase activity in the plasma from mice treated with Ec4-
ETA” 
 
  Treatment* 
 Ec4-ETA”  PBS 
 Mouse1 Mouse2 Mouse3 Mouse4  Mouse1 Mouse2 
ALT U/l 34 84 57 41  134 40 
AST U/l 141 200 138 85  177 62 
 
 
*Mice received 3 x 30 µg of Ec4-ETA” or PBS i.v. Activity of the transaminases 
was measured 24 h after the final injection. 
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Discussion 
 
Chemotherapy still has remained the mainstay of cancer therapy. The 
great majority of approved treatments have no inherent specificity for tumor 
cells but attack all dividing cells. More recently many investigations have been 
carried out to couple a toxic principle to a recognition function. Immunotoxins 
based on Pseudomonas aeruginosa exotoxin A (ETA, also termed PE), particularly 
its truncated variant carrying a C-terminal KDEL peptide (ETA"), have been 
generated against various cell surface receptors and extensively tested in 
preclinical and early clinical studies (4, 31). Most of them use a single-chain 
fragment (scFv) or a disulfide-stabilized dsFv fragment of antibodies as targeting 
moiety. We previously also reported on the potent anti-tumor effect of an 
EpCAM-specific scFv-ETA" immunotoxin (10), which is currently under phase II 
clinical investigation (8). 
Commonly used antibody Fv-based formats, however, are difficult to 
produce in high amounts when compared to other proteins and are often 
notoriously aggregation-prone (23-24, 32). ScFv and dsFv fragments used for 
tumor-targeted fusion proteins are commonly expressed in the periplasm or 
need to be refolded after expression in inclusion bodies.  
Here, we investigated another class of highly advanced binding 
molecules, Designed Ankyrin Repeat Proteins (DARPins), for targeted delivery of 
ETA" to tumor cells in vitro and in vivo. DARPins can be selected for high affinity 
which is a major requirement for efficient tumor targeting (33), their inherent 
robustness allows easy conjugation with various types of effector molecules, and 
pharmacology and tumor targeting properties can be easily modulated, e.g. by 
site-specific PEGylation. Therefore, we are not limited to the simple fusions 
described here, the molecules are robust enough to allow efficient production of 
more complicated constructs. 
We are expressing the DARPin-ETA" fusions in the cytoplasm of E. coli and 
find that these fusion proteins are produced in soluble form. Even though the 
ETA part contains two disulfide bonds, which appear to be beneficial in the 
internalization process (34), we find that they have been formed almost 
quantitatively after the protein has been purified, possibly by air oxidation. Thus, 
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we can use the convenient production of DARPins in the E. coli cytoplasm also 
with the DARPin-ETA" fusion proteins. 
A major challenge for the application of immunotoxins is the choice of 
targets which provide sufficient tumor specificity and, at the same time, promote 
intracellular delivery of the payload. Most tumor-targeting with fusion toxins has 
been studied in hematopoietic malignancies, but even there, only one 
(denileukin diftitox, Ontak®) finally received FDA approval (35).  
EpCAM is overexpressed in many solid tumors and on basolateral cell 
surfaces of some normal epithelia (14, 17) where it is, however, poorly accessible 
to circulating anti-EpCAM antibodies (16). Recently, EpCAM was also identified as 
a marker of cancer-initiating cells in colon (20), breast (21) and pancreatic 
cancers (22). Since cancer stem cells respond poorly to standard therapy and 
thus are largely responsible for treatment failure, their elimination must be a 
prime objective for all kinds of innovative cancer therapy. Thus, from a 
therapeutic point of view, EpCAM is more interesting as a docking site for 
targeting ligands delivering external effector molecules. In fact, EpCAM 
efficiently mediates internalization of bound ligands by receptor-mediated 
endocytosis and thus perfectly matches the need of anti-cancer agents acting on 
intracellular targets, such as protein toxins, chemotherapeutic agents, and 
antisense compounds (10-12).  
Recently, we have described for the first time the production and 
biochemical characterization of EpCAM-specific DARPins, and a first generation 
binder was used to successfully deliver therapeutic siRNA into tumor cells in the 
form of mono- and multivalent binders fused to highly charged protamine (13). 
Subsequent affinity maturation efforts then resulted in DARPin Ec4, which 
displayed affinity to EpCAM in the subnanomolar range and excellent biophysical 
properties (Martin-Killias et al., in preparation). 
We measured good tumor localization of Ec4-ETA", but not of the control 
fusion off7-ETA" by in vivo fluorescence imaging upon systemic administration in 
a HT29 colon carcinoma xenograft model. These data showed that localization in 
the tumor was specific and dependent on EpCAM binding with peak tumor 
accumulation 48-72 h after injection.  
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Fluorescent imaging records the distribution of molecules at any 
particular time point, while the previously used residualizing label 99mTc(CO)3 (33) 
gives an integral localization since the begin of injection, since any label will 
accumulate at the site of cellular internalization. This probably accounts for the 
difference in kidney accumulation, which is seen to decay rapidly when 
measured by fluorescent imaging but not by 99mTc(CO)3 radioactivity. While 
immunotoxins (scFv fragments or DARPins fused to a protein toxin such as ETA) 
would be expected to not fall in an ideal MW range for maximum accumulation 
(33), we see very encouraging enrichments and therapeutic effects already with 
the constructs described here, and there may be even better effects with 
different molecular formats. 
In the present study, Ec4 was fused with ETA" to assess for the first time 
the potential of a rationally engineered DARPin for tumor targeting and therapy. 
The fusion protein could indeed be well produced in soluble form in E. coli (at 
about 80-fold higher yield from shake flasks than our previously described scFv-
ETA" fusion toxin (4D5MOCB-ETA) (10), could be easily purified and was stable 
and resistant to aggregation. This will facilitate subsequent scaling up of the 
production process required for clinical trials.  
We found that the high affinity binding of Ec4 to intact cells was fully 
preserved upon fusion with ETA" and that Ec4-ETA" showed extremely high and 
specific in vitro cytotoxicity against EpCAM-positive tumor cells of various 
histotypes with IC50 values of 0.005 pM. This is remarkably low compared to 
other immunotoxins (36-38) and likely mirrors its high stability, affinity and 
efficient internalization by receptor-mediated endocytosis. These data, 
combined with efficient tumor targeting, indeed translated into potent anti-
tumor effects at well-tolerated doses with some mice showing complete 
regression of their tumors. The repeatable response measured after repeated 
injections further suggests that tumors retained a stable EpCAM expression 
profile and that antigen loss did not occur during treatment. 
A phase II study with a previously reported EpCAM-specific immunotoxin 
consisting of ETA" fused to a scFv antibody is ongoing and will be completed 
soon (8). Based on the findings of this study, it is tempting to speculate that 
DARPins like Ec4 will replace the antibody fragment as cell binding ligands also in 
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forthcoming generations of tumor-targeted fusion toxins as well as other drug 
delivery systems. 
In summary, we describe for the first time the generation and preclinical 
evaluation of an EpCAM-specific fusion toxin consisting of a high-affinity DARPin 
(Ec4) and ETA" as a catalytic biotoxin. We provide evidence for its potent activity 
against various tumor cell types in vitro, and its favorable tumor localization and 
anti-tumor activity in vivo. The advantages of DARPins enabling high yield 
expression, resistance against aggregation, and stability also in the form of fusion 
toxins in conjunction with a highly selective tumor-associated target like EpCAM, 
opens new avenues for the generation of rationally designed protein 
therapeutics with outstanding efficacy. 
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General conclusions and future perspectives 
 
The improvements in translating discoveries in molecular biology into 
diagnostics for and treatments of cancer have significantly broadened the 
spectrum of available therapeutics. Cancer treatments are shifting from 
chemotherapeutic drugs or radiotherapy towards treatments directed to the 
individual tumor type. Treatments can now be based on cancer-specific biologic 
mechanisms and, more importantly, can be tailored to the molecular specificity 
of a tumor type. The advantage of tumor targeted approaches is the reduction of 
systemic toxicity through selective delivery of drugs to the tumor. In addition, 
these approaches can provide powerful anti-cancer agents acting by alternative 
mechanisms, thus being effective on tumors that do not respond to or have 
acquired resistance to traditional therapies (1). One such concept is represented 
by immunotoxins. They mostly make use of monoclonal antibodies or fragments 
thereof for the specific delivery of a toxin to tumor cells (2). In this context, only 
the binding site of the antibody is required to localize the cytotoxic moiety in 
tumors. As tight binding is not restricted only to antibodies, alternative binding 
scaffolds with more favorable properties compared to antibodies, such us 
robustness, ease of modification and cost-efficient production could be 
beneficially used as targeting moiety. 
The concept of alternative binding proteins, based on new scaffolds with 
superior properties, has undergone rapid development and has been proven by 
different approaches (3). DARPins are a promising alternative to antibodies and 
have demonstrated to be valuable tools for a wide range of applications. In vitro 
selection techniques such as ribosome display and phage display have allowed 
the selection of high-affinity DARPins against a variety of different targets and 
their functionalities are explored in numerous assays. The first binders were 
obtained using ribosome display and specifically recognized maltose binding 
protein and two eukaryotic kinases (4). Since then, there has been an increasing 
number of selected DARPins towards a broad range of target proteins. E.g., 
several inhibitors have been selected from DARPin libraries demonstrating a 
potential for modulation of protein function in vitro and in cellulo (5-6). High 
affinity binders against members of the human mitogen activated protein kinase 
(MAPK) family were selected previously (7) and their potential applications as 
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intracellular inhibitors are currently being studied (P. Parizek, personal 
communication). Other examples of enzyme inhibition are DARPins capable of 
inhibiting the tobacco etch virus protease, a plant pathogen. A highly specific 
caspase-2 inhibitor was selected showing an allosteric mechanism of inhibition 
(8). DARPins were also successfully selected against CD4; here, a specific DARPin 
could potentially block HIV entry (9). Targeting the immunoglobuling E receptor, 
DARPins could prevent the release of proinflamatory mediators (10). In the field 
of oncology, several DARPins have been selected against a variety of relevant 
targets. The first example described DARPins binding to the tumor antigen HER2. 
These were successfully used for staining of sections of breast carcinoma and it 
was possible to evolve them to picomolar binders (11-12). In addition, bivalent 
HER2 binders (Tamaskovic and Jost et al., in preparation) and EGFR-specific 
DARPins (Boersma et al., in preparation) are showing promising cytotoxic effects. 
Taken together, these examples illustrate the wide applicability of DARPins. 
In the first part of my thesis (chapter II), I focused on the selection of 
DARPins against the extracellular domain of the clinically validated tumor-
associated antigen EpCAM. EpCAM is a particular interesting target due to its 
high expression in a plethora of tumors. The accessibility of its extracellular 
domain as well as its rapid internalization makes it an ideal target for the delivery 
of anti-tumor agents (13). To select DARPins specifically recognizing EpCAM, both 
phage and ribosome display techniques were used. The application of both 
selection procedures with different combinatorial DARPin libraries was 
particularly effective to select a variety of EpCAM binders. The best binder in 
terms of affinity, Eph1, has a particular deletion of two amino acids. This deletion 
appears to be important for tight binding to EpCAM since correcting it markedly 
reduced EpCAM binding. This binder shows a self-association tendency probably 
due to particular features of its sequence as analyzed by ROSETTA (14). Using 
affinity maturation, six improved second generation EpCAM-specific DARPins 
were generated, four of which were derived from EPh1. The evolved EPh1-
derived binders have the same randomized positions as well the characteristic 
two amino acid deletion, but four to six framework mutations. They were 
monomers, indicating that the dimerization or oligomerization tendency was 
abolished by the framework mutations introduced during directed evolution. The 
high affinity of these EpCAM-specific DARPins, a major requirement for efficient 
tumor targeting, in conjunction with the favorable properties of EpCAM as a 
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molecular target, provided an ideal starting point for the generation of fusion 
proteins delivering a toxic payload to EpCAM-expressing tumors.  
In the second part of my thesis (chapter III), the focus was on the 
generation of cytotoxic fusion proteins using one of the characterized EpCAM-
specific DARPins (Ec4). Ec4 was genetically fused to a truncated form of the 
potent bacterial toxin Pseudomonas exotoxin A (ETA"), and analyzed for its 
cytotoxic effect on tumor cells. Ec4-ETA" was expressed in soluble form in E. coli 
and purified with at least 80-fold higher yields as its counterpart, an EpCAM-
specific scFv_ETA fusion protein expressed in the periplasm (15). This remarkable 
increase in yield can be attributed to the favorable properties of DARPins in 
means of expression and purification. Consequently, using a DARPin as targeting 
moiety fused to ETA" was highly advantageous. 
To demonstrate that cytotoxicity was mediated by receptor-specific 
uptake, Ec4-ETA" was tested in a variety of tumor cell lines of different 
histological origin. Ec4-ETA" was highly cytotoxic to cells expressing EpCAM but 
not to EpCAM-negative cells. The cytotoxic effect was dependent on EpCAM 
binding as it was markedly reduced when the cells were preincubated with Ec4 
as a competitor but not with an unspecific DARPin. In addittion, unspecific 
DARPin-ETA" fusions showed cytotoxic effects at much higher concentrations.  
To translate the success of a targeted agent from in vitro or in cellulo to in 
vivo depends in part on the ability of the targeted drug to reach and penetrate 
the tumor. The distribution of a drug in a tumor depends on several factors and 
is a complex process involving extravasation from tumor capillaries, diffusion 
through the tumor interstitium, systemic clearance and drug degradation in the 
tumor tissue (16). Recently, it was demonstrated that for small proteins like 
DARPins tumor accumulation was proportional to affinity (17). Small proteins 
accumulated rapidly into tumors but required high affinity to be retained there 
as unbound molecules were cleared from the tumor rapidly. In contrast, larger 
molecules, in a size range larger than the kidney filtration cut off, can achieve 
good tumor accumulation with less affinity. Their decreased vascular 
extravasation can be compensated by a decrease in systemic clearance, 
producing a net increase in tumor uptake (18) . Intermediate molecules, such as 
DARPin-toxin fusions, are in an unfavorable situation. Their capillary 
extravasation to tumors is diminished but they are probably still partially 
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eliminated by the kidneys (17-18). Nevertheless, Ec4-ETA" showed specific tumor 
accumulation in a mouse xenograft model for human colon adenocarcinoma 
with a peak 48-72 h post injection. Tumor accumulation was translated in 
antitumor activity demonstrating the ability of Ec4-ETA" to remain stable in 
serum, gain access into tumors and cells, and inhibit tumor growth. Both dose 
treatments, 30 µg given 3 times (30/3) or 20 µg given 6 times (20/6) of Ec4ETA", 
were effective to significantly delay tumor growth and some mice showed 
complete tumor regressions. No systemic toxicity was observed as evaluated by 
mice weight data and liver enzymes determination. The percent of 
treatment/control (PBS) average tumor volume calculated at the end of the 
experiment (day 31) was 92 % for the unspecific DARPin_toxin, off7-ETA"; 19% 
for Ec4-ETA" 30/3; and 9% for Ec4-ETA" 20/6. This indicated that more regular 
doses were more effective to reduce tumor growth. Further studies will be 
needed to extend these findings to other cell lines and models. 
Although both dose schedules delayed tumor growth significantly during 
treatment, when complete regression was not achieved, tumors resumed growth 
around one week after the treatment finished. Probably Ec4-ETA" effectiveness 
was compromised because it was not able to access all tumor cells. Those cells 
that were not targeted by the DARPin-toxin were able to start growing again 
when treatment was discontinued. Other dose schedules and molecular formats 
should be evaluated to achieve more effective tumor penetration.  
It must be noted that two major problems should be addressed when 
working with ETA based immunotoxins independent of the targeting moiety: ETA 
immunogenicity and unspecific toxicity, to which liver and endothelial cells are 
the most susceptible. However, ETA-based immunotoxins are under further 
development to reduce these unspecific side effects and these approaches 
should also be applicable to DARPin-ETA fusions. Engineering of less 
immunogenic ETA variants, PEGylation, the use of immunosuppresive agents, 
and inhibition of TNF-alpha production in the liver are some of the approaches 
proposed for the improvement of the efficacy of immunotoxins (19-23).  
The high number of preclinical and clinical trials carried out with a variety 
of immunotoxins (24) demonstrates that immunotoxins are suitable as potent 
anti-cancer agents.  
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Future perspectives 
DARPins advantages, specifically their robustness combined with cost-
efficient production, make them ideal tools to be used for both diagnostic and 
therapeutic applications. For the first time, EpCAM-specific and high affinity 
DARPins were selected and characterized. As a proof of principle, this project has 
demonstrated the suitability of DARPins for the efficient delivery of ETA toxin to 
tumors in vivo. However, the application of the selected EpCAM-DARPins is 
certainly not restricted to the delivery of this particular toxin. There are different 
classes of payloads that have been used in targeted therapies to mediate cell 
killing, including toxins (as described here), cytokines, radionuclides, 
chemotherapeutics drugs and enzymes. Each of these approaches present 
advantages and disadvantages. Nonetheless, the specificity of these fusion 
proteins depends on the targeting moiety and DARPins are well suited to be 
equipped with such effector molecules. Numerous other applications can be 
envisioned such as in vivo tumor imagining (25) or tissue staining (11). Different 
molecular formats could be easily engineered such as dimers or multimers with 
different specificities which might be useful to bring reaction partners together 
(26). In addition, EpCAM-DARPins might be also helpful for the determination of 
EpCAM structure in crystallization trials (27). Further applications are currently 
being investigated, such as the generation of bivalent EpCAM-DARPins, a second 
generation of Ec4-ETA" with improved tumor specificity, and the development of 
nanoparticles in which Ec4-ETA" is encapsulated. 
It is clear that in a time of rising healthcare costs, the cost of a 
therapeutic agent is a major point of concern. In this respect and due to their 
improved biophysical properties the use of DARPins as therapeutic agents will be 
of great advantage facilitating the upscaling of the production process and 
providing an economical advantage. The results obtained here strongly 
encourage further exploration of EpCAM-DARPins in therapeutic applications.  
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